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ABSTRACT 
Antimicrobial peptides (AMPs) are relatively short peptides endowed with broad 
spectrum antimicrobial, anti-inflammatory immunomodulating and wound healing 
enhancement activity. They are essential components of the innate immune system of 
higher eukaryotes providing the first line of defense against microbial invasions. AMPs 
are extremely heterogeneous in length, structure, aminoacid composition and, more 
importantly, molecular mechanism of bacterial killing. From this point of view AMPs can 
be divided in at least four wide classes: (i) cationic antimicrobial peptides (CAMPs); (ii) 
anionic antimicrobial peptides (AAMPs); (iii) histidine-rich antimicrobial peptides 
(HAMPs), and (iv) AMPs with intracellular targets (DNA, RNA, ribosomes, chaperons, 
enzymes). 
The pharmacological potential of AMPs, and especially of AMP mixtures, is obvious. 
However the costs of pharmaceutical formulations including two or more peptides 
separately produced would be so high that even a very interesting pharmacological 
activity would not compensate for the effort needed to prepare the mixture. Accordingly, 
the aim of the present project is to develop a strategy to prepare mixtures of two or 
more AMPs with costs, production times and amount of work comparable to those 
necessary for the production of a single recombinant AMP. 
Two alternative strategies were evaluated, one exploiting a previously optimized-carrier 
protein for the production of recombinant AMPs as fusion proteins, and an alternative 
strategy aiming to prepare a carrier-less precursor composed only by AMP modules. 
The carrier developed by our group, ONC-DCless-H6, was able to effectively drive to 
inclusion bodies both a highly cationic sequence of about 50 residues [(P)PAP-
A3(Pro26)] containing two CAMP-like sequences and a modular sequence (AT2H) of 
more than 100 residues including 2 anionic, 2 cationic and a histidine rich module. In 
both cases expression yields were high (>200 mg/L and >100 mg/L, respectively). 
Purification by IMAC provided a protein with good yield and purity. Purified recombinant 
proteins were hydrolyzed in 0.1 M acetic acid at 60°C to cleave the acid labile Asp-Pro 
sequences at the junction sites between consecutive AMP modules. The efficiency was 
very high in the case AT2H, which provided only the desired peptides, thus indicating 
that all the acid labile Asp-Pro sequences underwent cleavage with an efficiency higher 
than 95%. Only in the case of (P)PAP-A3(Pro26), the internal Asp-Pro sequence was 
cleaved with an efficiency of only about 85%. The comparison of the sequences 
adjacent to the different Asp-Pro cleavage sites in (P)PAP-A3(Pro26) and AT2H 
suggested that in order to obtain a very high cleavage efficiency a flexible sequence, 
rich in small and/or coil-preferring amino acids should be present at least on one side of 
the Asp-Pro site. This information will be useful for the design of further fusion proteins. 
The carrier-less strategy was tested by preparing two modular precursors, AT5H 
(containing 5 anionic, 5 cationic and a histidine rich module) and AT4LH (containing 4 
anionic, 4 cationic and a histidine rich module). AT5H and AT4LH showed relatively low 
expression levels (15 and 30 mg/L, respectively) and a different behavior of the 
inclusion bodies formed upon recombinant expression. In fact, the inclusion bodies, 
differently from those generated by ONC-DCless-H6, were soluble in 2 M urea thus 
suggesting a lower compactness/stability. A possible cause of the low expression levels 
could be the non-optimal codon usage of the coding sequences necessary for avoiding 
the presence of identical direct repeats which would have made difficult the chemical 
synthesis of the coding sequences. Low expression levels, in turn, could have 
contributed to the formation of “unstable” inclusion bodies. Indeed, it is well known that 
inclusion bodies formation is generally related to high expression levels. In the future, 
alternative approaches based on ligation of multiple copies of a smaller fragment could 
allow preparing coding sequences where all the repeats have an optimal codon usage. 
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RIASSUNTO 
I Peptidi AntiMicrobici (AMP), sono peptidi relativamente corti dotati di attività 
antimicrobica ad ampio spettro. Sono componenti essenziali del sistema immunitario 
innato degli eucarioti superiori e rappresentano la prima linea di difesa contro le 
invasioni microbiche. Gli AMP sono estremamente eterogenei in lunghezza (da circa 
15 a 50-60 residui), struttura secondaria e terziaria, composizione amminoacidica e 
meccanismo d’azione. Gli AMP possono essere divisi in almeno quattro classi: 
• peptidi antimicrobici cationici (CAMP), il cui bersaglio sono le membrane; 
• peptidi antimicrobici anionici (AAMP), il cui bersaglio sono i cationi metallici (e in 
secondo luogo le membrane); 
• peptidi antimicrobici ricchi di istidine (HAMP), il cui bersaglio sono i cationi metallici (e 
in secondo luogo le membrane); 
• AMP con bersagli intracellulari (DNA, RNA, ribosomi, enzimi). 
Va ricordato che le 4 classi non sono ben separate. In particolare, molti AMP 
appartenenti alle prime tre classi possono possedere anche un bersaglio intracellulare. 
I CAMP hanno una carica netta positiva per l'abbondanza di residui di lisina e arginina 
e sono ricchi di residui idrofobici. Essi sono quindi in grado di acquisire una struttura 
anfipatica che permette loro di perturbare le membrane delle cellule batteriche e 
causarne la morte. Inoltre, alcuni CAMP interagiscono con bersagli intracellulari. Per 
esempio la Buforina II attraversa le membrane batteriche e si lega al DNA interferendo 
con la divisione cellulare e con la sintesi proteica. 
AAMP e HAMP sono meno caratterizzati dei CAMP. In alcuni casi è stato dimostrato 
che la loro azione antimicrobica è dipendente dalla presenza di ioni metallici come, ad 
esempio, lo zinco: il complesso peptide/metallo si lega alle membrane batteriche 
compromettendone il funzionamento. Pertanto, sotto forma di complessi con i metalli, 
questi peptidi potrebbero mimare l’azione dei CAMP. Esempi sono la dermcidina, un 
AAMP presente nella pelle, e la “glicoproteina ricca di istidine”, una delle più 
abbondanti proteine sieriche, caratterizzata dalla presenza di un dominio costituito da 
ripetizioni HXHXH. 
Il peculiare meccanismo d'azione dei CAMP ne fa un’alternativa agli antibiotici 
convenzionali. Infatti, le cellule microbiche possono acquisire resistenza ai CAMP solo 
attraverso modifiche della loro composizione di membrana. Ma tale cambiamento non 
solo richiederebbe diverse mutazioni, ma potrebbe anche essere dannoso per lo 
stesso batterio poiché la membrana citoplasmatica possiede funzioni metaboliche 
essenziali tra cui la catena di trasporto degli elettroni e la sintesi di ATP. Le diverse 
classi di AMP verosimilmente cooperano tra loro così da ottimizzare l’azione 
battericida: AAMP e HAMP possono rallentare la crescita batterica sottraendo cationi 
metallici essenziali alla crescita; CAMP, AAMP e HAMP, possono uccidere 
direttamente i batteri, ma anche facilitare la penetrazione degli AMP che legano 
bersagli intracellulari. Ad esempio i CAMP capaci di legare gli LPS possono apportare 
danni alla membrana esterna aumentandone la permeabilità. Non sorprende quindi 
che tutti i fluidi corporei contengono miscele complesse di diversi AMP.  
Il potenziale farmacologico degli AMP, e in particolare delle miscele di AMP, è 
evidente. Tuttavia, l'uso di peptidi come farmaci è ostacolata dagli elevati costi di 
produzione. Un peptide (o proteina) è preso in considerazione per lo sviluppo di un 
farmaco solo quando un farmaco convenzionale non è disponibile o il peptide è 
significativamente migliore rispetto al farmaco convenzionale dal punto di vista 
farmacologico. D'altra parte, i costi di una formulazione farmaceutica che includa due o 
più peptidi prodotti separatamente sarebbe così elevato che anche un'attività 
farmacologica molto interessante non compenserebbe lo sforzo necessario per 
preparare la miscela. Solo nel caso di una miscela di peptidi preparata dalla scissione 
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di una singola proteina precursore, i costi potrebbero essere sufficientemente 
contenuti da ipotizzarne una produzione a livello industriale.  
Nel laboratorio dove si è svolto questo progetto di dottorato è stato sviluppato un 
sistema efficiente per la produzione di CAMP ricombinanti. Questi sono espressi fusi al 
C-terminale di un “carrier” derivato dell’onconasi (ONC-DCless-H6) una ribonucleasi 
che può essere espressa a livelli molto elevati all’interno di corpi inclusi (circa 150- 200 
mg/L). Usando questa strategia diversi CAMP di lunghezza compresa tra 18 e 50 
residui sono stati preparati ad una purezza maggiore del 98% con rese di circa 10-20 
mg/L di cultura. Anche se efficiente questo metodo potrebbe essere ulteriormente 
ottimizzato. Ad esempio, un AMP di 20 residui viene prodotto a partire da un 
precursore di circa 130 residui. Così dopo la scissione del peptide desiderato 110 
residui saranno scartati. Rese più elevate potrebbero essere ottenute aggiungendo più 
copie dell’AMP così da aumentare il rapporto AMP/ONC. Inoltre aggiungendo al carrier 
AMP differenti si potrebbe produrre una miscela di 2 o più AMP con la stessa 
procedura utilizzata per la produzione di un singolo AMP. 
Infine, dati di letteratura suggeriscono che si possano produrre miscele di AMP con 
una strategia non basata su un carrier. Ad esempio la buforina II, un CAMP che lega il 
DNA, è stata prodotta sotto forma di concatenati (MMIS-M-buforin II-M-)n dove MMIS è 
una sequenza anionica con densità di carica simile a quella della buforina che si è 
dimostrata essenziale per ottenere elevati livelli di espressione. 
L'obiettivo generale di questo lavoro di ricerca è lo sviluppo di metodi efficaci per la 
produzione di miscele di due o più AMPs ricombinanti che possano essere preparate 
attraverso una singola linea di produzione rendendo così i costi comparabili a quelli di 
una singola proteina ricombinante.  
Questo obiettivo è stato raggiunto attraverso due strategie: 
I) Utilizzando il carrier ONC-DCless-H6 precedentemente sviluppato, secondo gli 
schemi: 
ONC-DCless-H6-DP-CAMP1-DP-CAMP2 
& 
ONC-DCless-H6- (DP-AAMP-DP-CAMP) n 
dove "DP" è la sequenza acido-labile Asp-Pro necessaria per separare i moduli tra di 
loro e dal carrier. 
II) Preparando precursori artificiali modulari privi di carrier contenenti moduli AAMP e 
CAMP alternati che possano essere idrolizzati in una miscela AMP secondo lo 
schema: 
(AAMP-DP-CAMP-DP) n-TAG 
dove "TAG" è una breve sequenza tag o un AMP che può essere utilizzato come una 
sequenza tag durante la procedura di purificazione.  
Produzione di CAMP derivati dal peptide di attivazione del Pepsinogeno 
Al fine di verificare la possibilità di preparare proteine di fusione recanti più di un 
modulo CAMP, il peptide di attivazione della isoforma A3 del pepsinogeno (PAP-A3; 
47 aa) è stato selezionato come CAMP modello. Uno strumento bioinformatico che 
permette l'identificazione di peptidi antimicrobici criptici all’interno di una sequenza 
proteica sviluppato dal nostro gruppo di ricerca suggeriva la presenza di due ipotetici 
CAMP corrispondenti ai primi 25 e agli ultimi 22 residui del peptide. Pertanto, PAP-A3 
può essere considerato un esempio naturale di CAMP presenti in tandem in un 
precursore. Va notato che PAP-A3 contiene già un residuo di aspartato esattamente al 
limite previsto tra i due moduli (D25-F26). Pertanto, semplicemente inserendo un 
residuo di prolina tra i residui D25 e F26 è possibile ottenere un precursore contenente 
un sito sensibile all’idrolisi acida situato al confine tra i due moduli CAMP. Sono state 
quindi preparate due proteine di fusione ricombinanti, ONC-DCless-H6-(P) PAP-A3 e 
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ONC-DCless-H6-(P)PAP-A3(Pro26) che si differenziano per la presenza di una 
prolina. Le proteine sono state espresse in E. coli BL21(DE3) come corpi di inclusione 
a livelli molto elevati (circa 200-250 mg/L) e purificate mediante IMAC. La separazione 
dei CAMP dal carrier è stata ottenuta mediante idrolisi acida delle sequenze DP (in 
acido acetico/HCl pH 2). L’analisi SDS-PAGE ha mostrato che dopo 24 h di 
incubazione a 60°C, la sequenza DP che si trova nella regione linker di entrambe le 
proteine di fusione, è scissa efficientemente (circa il 95%). I peptidi sono stati purificati 
mediante precipitazione selettiva del carrier a pH 7,2.  
Le due miscele di idrolisi sono state analizzate mediante RP-HPLC e spettrometria di 
massa che ha consentito di identificare tutti i frammenti attesi. Nel caso di ONC-
DCless-H6-(P)PAP-A3 il 95% circa della miscela corrisponde al peptide desiderato 
(P)PAP-A3 e circa il 5% ai frammenti (P)IMY25 e FLK22 derivanti dall’idrolisi del 
legame Asp25-Phe26. Queste percentuali sono in accordo con le frequenze di idrolisi 
precedentemente determinate per sequenze Asp-X e dimostrano che il peptide 
desiderato di 47 residui può essere ottenuto con una perdita minima dovuta alla 
frammentazione del legame Asp25-Phe26. Nel caso di ONC-DCless-H6-(P)PAP-
A3(Pro26) sono stati identificati i tre peptidi previsti (P)PAP-A3(Pro26), (P)IMY25 e 
(P)FLK22. Tuttavia, l'analisi quantitativa ha mostrato che solo l’80% circa del peptide è 
stato idrolizzato in corrispondenza del legame Asp25-Pro26. L'efficienza di idrolisi 
inferiore del sito Asp25-Pro26 rispetto alla sequenza Asp-Pro nella regione linker è 
probabilmente dovuta ad un maggiore ingombro sterico delle sequenze circostanti non 
presente nel linker tra carrier e peptide.  
I peptidi sono stati purificati mediante RP-HPLC con un recupero di circa il 70%. La 
purezza dei peptidi è risultata essere superiore al 95%. (P)PAP-A3 è stato prodotto 
con una resa finale di circa 18-20 mg/L di coltura, mentre (P)IMY25 e (P) FLK22 sono 
stati prodotti con una resa finale di 7-8 mg/L della cultura per ciascun peptide. 
Pertanto, nonostante l’idrolisi incompleta del legame Asp25-Pro26, la strategia si è 
dimostrata adatta alla produzione contemporanea dei due peptidi ricombinanti. 
Nei saggi di attività antimicrobica (P)PAP-A3 ha mostrato valori di MIC simili o 
addirittura inferiori a quelle del peptide di controllo GKY20 su un pannello ampio di 
ceppi Gram (-) e (+). Per quanto riguarda i frammenti, (P)IMY25 ha mostrato un'attività 
significativa su tutti i ceppi mentre (P)FLK22 è risultato attivo solo su due ceppi. Nei 
saggi di attività anti-biofilm invece i peptidi (P)IMY25 e (P)FLK22 si sono mostrati più 
attivi di PAP-A3. Progettazione di precursori modulari privi di carrier 
Il secondo obiettivo di questo progetto di dottorato è stato la progettazione di un 
precursore modulare contenente moduli AAMP e CAMP alternati che formi corpi di 
inclusione non dannosi per l’ospite. Sono state progettate e sintetizzate due di tali 
proteine modulari: 
MKQDP-(FibA-DP-GKY20-DP) 5-HRP  (AT5H) 
 
MKQDP-(FibA-DP-GKY20-DP)2-L-(FibA-DP-GKY20-DP)2-HRP  (AT4LH) 
 
Dove GKY20 è un CAMP derivato dal C-terminale della trombina umana (20 aa; carica 
= +5); FibA è il fibrinopeptide A, un AAMP (16 aa; carica = -3;); HRP è un HAMP 
derivante dalla Histidine-rich glycoprotein umana (22 aa; carica = 0); L è un linker 
flessibile (6 aa; carica = 0). Le sequenze codificanti sono state ottenute mediante 
sintesi chimica. Solitamente durante la progettazione di una sequenza codificante 
sintetica, il codon usage viene adattato a quello dell'organismo ospite per ottenere 
elevati livelli di espressione. Tuttavia, nel caso delle sequenza codificanti AT5H e 
AT4LH questa strategia avrebbe comportato la presenza di 5 e 4 ripetizioni identiche, 
rispettivamente. Queste ripetizioni non solo rendono particolarmente difficile la 
preparazione del DNA sintetico ma potrebbero influenzare negativamente la 
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replicazione. Pertanto sono stati utilizzati due software, uno sviluppato da “GenScript” 
(AT5H) e uno da “Eurofin Genomics” (AT4LH) che permettono di minimizzare le 
ripetizioni sfruttando la degenerazione del codice genetico. Ovviamente questo ha 
reso impossibile rispettare pienamente il codon usage di E. coli. 
Entrambe le proteine modulari AT5H e AT4LH hanno mostrato livelli di espressione 
relativamente bassi (15 e 30 mg/L, rispettivamente) e la formazione di corpi di 
inclusione, che, diversamente da quelli generati da ONC-DCless-H6, erano solubili in 2 
M urea suggerendo una minore compattezza e/o stabilità. Una probabile causa dei 
bassi livelli di espressione potrebbe essere il codon usage non ottimale utilizzato per 
evitare la presenza delle ripetizioni nelle sequenze codificanti. I livelli di espressione 
bassi, a loro volta, potrebbero aver contribuito alla formazione di corpi di inclusione 
"instabili". Infatti, è noto che la formazione corpi di inclusione è associata generalmente 
ad elevati livelli di espressione.  
Clonaggio, espressione e purificazione di ONC-AT2H 
Dati i livelli di espressione insoddisfacenti di AT5H e AT4LH si è deciso di costruire 
una proteina di fusione, ONC-AT2H, unendo ONC-DCless-H6 con  la metà C-
terminale della proteina modulare AT4LH: 
ONC-DCless-H6-DP-(FIBA-DP-GKY20-DP) 2-HRP 
 
L'idrolisi acida completa di ONC-AT2H dovrebbe fornire una miscela di quattro peptidi 
nei seguenti rapporti molari: ONC-DCless-H6: (P) HRP: (P)FIBA(D): (P)GKY21 = 1: 1: 
2: 2. 
ONC- AT2H è stata espressa in E. coli BL21DE3 con una resa di circa 120 mg/L in 
forma di corpi inclusi resistenti al lavaggio con urea 2 M. 
Mediante IMAC la proteina è stata purificata con una resa del 95% e una purezza 
superiore al 90%. ONC-AT2H è stata quindi idrolizzata a 60°C, pH 2 per 24 h e il 
carrier rimosso mediante precipitazione frazionata. Mediante RP-HPLC e spettrometria 
di massa si è accertato che la miscela conteneva essenzialmente solo i tre peptidi 
attesi. La resa è stata di circa 15-16 mg della miscela di peptidi per litro di coltura. 
Confrontando i risultati con quelli ottenuti nel caso delle due proteine modulari si può 
concludere che ONC-AT2H fornisce rese più elevate con una procedura di 
purificazione semplice. 
Per studiare l'attività antimicrobica della miscela sono state effettuate curve dose-
effetto utilizzando (P)GKY20 e (P)GKY21 purificato dalla miscela come controlli. 
(P)GKY20 e (P)GKY21 hanno mostrato sostanzialmente la stessa attività mentre la 
miscela contenente anche (P)FIBA(D) e (P)HRP è risultata considerevolmente più 
attiva suggerendo che questi due AMP contribuiscono all’attività antimicrobica. Resta 
da determinare se l’attività della miscela sia la somma dei contributi dei tre peptidi o se 
invece non siano presenti interazioni di tipo sinergico.  
In conclusione, è possibile affermare che, anche se non tutti gli obiettivi iniziali sono 
stati pienamente raggiunti, questo lavoro di dottorato potrà aprire la strada allo 
sviluppo di miscele di peptidi farmacologicamente interessanti. 
 
Attività di ricerca svolta presso il laboratorio diretto dal Dott. Tam Mignot. 
Durante il periodo di ricerca all’estero, della durata di tre mesi, sono stata ospite 
presso il CNRS di Marsiglia nel Laboratorio di Chimica Batteriologia (LCB) del Dott. 
Tam Mignot.  
Il mio progetto ha previsto l’individuazione di punti di controllo nel sistema di 
regolazione chemiotattico di Myxoccoccus xanthus. 
M. xanthus è un batterio del suolo che cresce comunemente in terreno umido ricco di 
sostanza organica e che si muove con due sistemi geneticamente distinti. Il primo 
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sistema è chiamato sociale, (S) motility, e comporta il movimento delle cellule 
all’interno del gruppo. Il secondo sistema è chiamato avventuroso, (A) motility, e 
comporta il movimento delle singole cellule. Le cellule di M. xanthus invertono 
periodicamente la loro direzione di movimento e si pensa che queste inversioni 
cellulari siano necessarie nella regolazione della chemiotassi. In natura, quando cellule 
di M. xanthus non sono in grado di trovare le sostanze nutrienti sufficienti, entrano in 
un processo di sviluppo in cui si aggregano formando cumuli pigmentati, chiamati corpi 
fruttiferi. All'interno dei corpi fruttiferi, le cellule si differenziano per formare spore che 
sono cellule metabolicamente dormienti resistenti a periodi prolungati di digiuno, 
essiccazione, e temperature relativamente elevate.  
Il sistema chemiotattico Frz dirige la motilità in M. xanthus regolando la frequenza di 
reversione cellulare. Il sistema Frz è composto da: FrzCD, un chemiorecettore 
citoplasmatico; FrzA e FrzB, due proteine CheW-like; FrzE, una proteina di fusione 
CheA-CheY; FrzF, una metiltransferasi; FrzG, una metilesterasi; e FrzZ, una fusione 
CheY-CheY. Partendo da queste premesse il progetto ha previsto: 
i)La costruzione del ceppo ∆frzA ∆frzB frzBAβ4β5  per produrre la Chimera 
FrzBAβ4β5. 
Il sistema Frz, presenta due proteine CheW-like, FrzA e FrzB. Ci siamo chiesti perché 
il sistema Frz avesse bisogno di due CheW-like. Da analisi cristallografiche è emerso 
che una regione di 20 amminoacidi che forma due foglietti beta, è presente in FrzA ma 
non in FrzB. Questo suggerisce che FrzB manca della regione di legame a FrzE. 
Abbiamo quindi costruito un ceppo ricombinante producente una proteina chimerica 
chiamata FrzBAβ4β5, ottenuta con l'introduzione dei 21 amminoacidi formanti i due 
foglietti beta di FrzA, in FrzB. Il ceppo risultante, ∆frzA ∆frzB frzBAβ4β5, ha risposto 
all’IAA (isoammil alcool, un attivatore del sistema), il che significa che la chimera può 
legarsi all’istidin-chinasi e FrzA è la CheW-like principale del sistema. 
ii)Produzione del mutante FrzCD∆131-180.  
I recettori canonici di E.coli, comprendono un dominio transmembrana, un dominio di 
legame al ligando, un dominio HAMP, ed una regione di segnalazione. L’HAMP è una 
regione flessibile che cambia quando i recettori rilevano il segnale e trasferiscono il 
cambiamento conformazionale al dominio di metilazione. Invece, il recettore FrzCD di 
M. xanthus, non ha domini transmembrana ed ha un dominio HAMP degenerato. E' 
quindi un recettore citoplasmatico. La regione che si estende dall’amminoacido 7 al 27 
ha amminoacidi carichi positivamente, ed ha un ruolo molto importante nel legame al 
DNA, mentre la regione che va da 131 a 180 ha una funzione ancora sconosciuta.  
Per comprendere il ruolo della porzione 131-180 ho effettuato la delezione di questa 
stessa, ed ho quindi creato il mutante chiamato frzCDΔ131-180.  
Dopo aver ottenuto il plasmide ho richiesto il suo sequenziamento. Ho utilizzato questo 
plasmide per trasformare M. xanthus e attraverso il metodo della doppia selezione e 
ricombinazione ho ottenuto il mutante. Una volta effettuato uno screening delle 
colonie, ho effettuato la selezione con il galattosio. Avendo utilizzato un sistema di 
doppio ricombinante, questo tipo di selezione mi ha garantito che le colonie che 
presentavano un alone hanno subito una singola ricombinazione, rappresentando 
quindi le WT, mentre quelle che non presentano un alone hanno subito la doppia 
ricombinazione e pertanto rappresentavano i mutanti di interesse.  
Questo perché se avviene una singola ricombinazione, il gene wt verrà ricostituito, 
mentre se si verificano entrambe le ricombinazioni ci sarà un riarrangiamento dei geni 
e si otterrà il nostro mutante di interesse. 
Nella nostra analisi del fenotipo, il mutante frzCDΔ131-180, non mostra ne espansione 
delle colonie ne corpi fruttiferi. Questo fenotipo è dovuto al fatto che le cellule sono in 
iper-reversione e non possono produrre un affollamento netto. 
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1.1 Antimicrobial peptides 
Antimicrobial peptides (AMPs) are relatively short peptides endowed with a 
broad spectrum of antimicrobial activity (Fig. 1.1). They are essential components 
of the innate immune system of higher eukaryotes providing the first line of defense 
against microbial invasions. AMPs are extremely heterogeneous in length (from 
about 15 to 50-60 residues), secondary/tertiary structure (Fig. 1.2), aminoacid 
composition and, more importantly, molecular mechanism of bacterial killing. From 
this point of view AMPs can be divided in at least four classes: 
I. cationic antimicrobial peptides (CAMPs) which target membranes. 
II. anionic antimicrobial peptides (AAMPs) which target metal cations (and 
membranes). 
III. Histidine-rich antimicrobial peptides (HAMPs) which target metal cations 
(and membranes). 
IV. AMPs with intracellular targets (DNA, RNA, ribosomes, chaperons, 
enzymes). 
 
However, it should be remembered that the 4 classes are not well separated. In 
particular, several AMPs belonging to the first three classes sometimes also interact 
with intracellular targets. 
CAMPs, as their name suggests, have a positive net charge due to the abundance 
in lysine and arginine residues and are rich in hydrophobic residues. They are 
consequently able to acquire an amphipathic structure which allows them to perturb 
bacterial membranes, their main target, leading to cell death (Fig. 1.3). The net 
positive charge drives the initial adsorption to the surface of bacterial membranes, 
very rich in negative charges due to anionic lipids such as phosphatidylglycerol or 
lipopolysaccharides. The amphipathic nature of CAMPs causes their insertion into 
the membrane and the opening of pores which cause osmotic lysis [1]. On the 
contrary, in eukaryotic membranes, anionic phospholipids are sequestered in the 
inner leaflet and thus no electrostatic interaction can be established [2]. This 
important molecular feature is the basis of the selectivity of CAMPs towards 
bacteria. It should be reminded however, as already mentioned, that some CAMPs 
have intracellular targets. For example, Buforin II crosses bacterial membranes and 
binds to DNA, interfering with cell division and protein synthesis. 
AAMP and HAMPs are less known than CAMPs. In some cases, it has been 
demonstrated that the antimicrobial action of these AMPs is dependent on the 
presence of metal ions like zinc: the metal/peptide complex would bind to the 
bacterial membranes thus impairing their function. Therefore, in the metal bound 
form, these peptides would mimic CAMPs. Examples are dermcidin, an AAMP 
present in the skin, and Histidin-rich glycoprotein, a HAMP of serum, and three 
small antimicrobial anionic peptides (SAAPs), GA(D)5, G(D)6, and (D)7, present in 
pulmonary surfactant. SAAPs are peculiar as they also interact with an intracellular 
target. In the presence of zinc, they penetrate membranes without inducing any 
morphological change. Once in the cytoplasm, SAAPs bind to and inhibit 
ribosomes.  
However, it has been suggested that AAMPs and HAMPs could also exert an 
indirect antimicrobial effect by scavenging essential metals (Zn, Fe, Cu, Mn, Co 
etc.), thus impairing bacterial growth. 
In higher eukaryotes AMPs are secreted by many cell types in several different 
tissues. Moreover, some AMPs are expressed constitutively, whereas other are 
finely modulated. Very interestingly several AMPs are expressed constitutively at 
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low levels but their expression can be increased in response to different stimuli. The 
regulation of expression is particularly well known in the case of human CAMPs, the 
cathelicidin LL-37 and the alpha and beta defensins ([3] and references therein). 
For example, LL‑37 is expressed constitutively in many cell types but in epithelial 
cell its expression is modulated by inflammatory triggers such as wounding or 
infections [3]. In addition, the expression of LL‑37 is induced by vitamin D3. Human 
beta defensin 1 (HBD1) is constitutively expressed in epithelial cells, whereas 
human beta defensins 2 and 3 are induced by NF-κB and TNF, respectively ([3] and 
references therein). Finally human beta defensin 4 is induced by the combined 
action of bacteria and TNF ([3] and references therein). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Schematic representation of multiple action of antimicrobial peptides.  
AMP, anti-microbial peptide; LPS, lipopolysaccharide. 
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Figure 1.2: Example of structures of antimicrobial peptides.  
Structural diversity and classification of natural antimicrobial peptides. The known structures of 
AMPs are classified into four families (α, β, αβ, and non-αβ) and the structural family for each 
peptide is indicated at the left bottom corner of each panel. (from Wang G. 2013) 
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Figure 1.3: Key mechanisms of bacterial membrane disruption by antimicrobial peptides. 
Events occurring at the bacterial cytoplasmic membrane following initial antimicrobial peptide (AMP) 
adsorption. These events are not necessarily exclusive of each other. In the classical models of 
membrane disruption, the peptides lying on the membrane reach a threshold concentration and insert 
across the membrane to form either peptide-lined pores in the barrel-stave model, solubilize the 
membrane into micellar structures in the carpet model, or form peptide-and-lipid-lined pores in the 
toroidal pore model. In the revised disordered toroidal pore model, pore formation is more stochastic 
and involves fewer peptides. The thickness of the bilayer can be affected by the presence of the 
peptides, or the membrane itself can be remodeled to form domains rich in anionic lipids surrounding 
the peptides. In more specific cases, non-bilayer intermediates in the membrane can be induced; 
peptide adsorption to the membrane can be enhanced by targeting them to oxidized phospholipids; a 
peptide may couple with small anions across the bilayer, resulting in their efflux; the membrane 
potential can be dissipated without other noticeable damage; or conversely, in the molecular 
electroporation model, the accumulation of peptide on the outer leaflet increases the membrane 
potential above a threshold that renders the membrane transiently permeable to various molecules 
including the peptides themselves. (from Leonard T. Nguyen, 2011). 
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1.2 Cryptic AMPs and AMP-releasing proteins 
Microbial cells might acquire resistance to CAMPs and other membrane 
targeting AMPs only through the modification of the membrane composition [1]. 
Such a change not only would require several mutations, but could also be 
detrimental to bacterial cells as their cytoplasmic membrane has several essential 
metabolic functions including electron transport chains and ATP synthesis. 
However, some strains have acquired a limited resistance to antimicrobial peptides 
by producing specific proteases like, for example, “omptins” of enterobacteria and 
V8 proteases of Staphylococcus ssp. [4-5]. However, multicellular eukaryotes have 
developed a very interesting countermove to defend from the attack of bacterial 
cells: the secretion of “AMP-Releasing Proteins” (AMP-RPs, usually >100 aa) which 
release active peptides only after a partial proteolytic processing operated by host 
and/or bacterial proteases. Thus, a bacterial strain that secretes proteases to 
escape AMPs would "suicide” by releasing “cryptic” AMPs from these precursors. 
This mechanism has been demonstrated for Zf-3 a ribonuclease from Danio rerio 
[6]. Surprisingly, several proteins with functions not necessarily related to host 
defense can behave as sources of CAMPs. Some examples are hemoglobin, 
thrombin, lactoferrin, lysozymes, histone-like proteins and vertebrate secretory 
ribonuclease. Lysozyme is a well-known example: it exerts bactericidal action by 
hydrolyzing peptidoglycan but, if inactivated by proteolysis, it releases CAMPs [7]. It 
is well established that mammalian’s lactoferrin, a multifunctional protein, 
possesses bactericidal determinants in the positively charged helix at the N-
terminus. Proteolysis in the stomach of infants leads to the release of a 25-aa 
peptide, which is more bactericidal than the native protein on several strains, 
including antibiotic-resistant strains [8-9]. More recently it has been demonstrated 
that human thrombin, a key enzyme in the coagulation cascade, contains 
bactericidal determinants in the C-terminal region. It is worth noting that a peptide 
deriving from this region of thrombin has been detected in vivo in human wounds 
[10-11]. 
Also fibrinopeptides are examples of “cryptic” AAMPs. In fact, these small anionic 
peptides that are released from fibrinogen to allow the formation of the fibrin cloth, 
have also antimicrobial activity.  
 
1.3 Additional biological activities of AMPs 
In addition to direct bacteria killing some CAMPs have key modulatory 
functions in the innate immune response including the ability to inhibit LPS-induced 
production of proinflammatory cytokines, chemotaxis, induction of cytokine release 
and anti-inflammatory activity [12]. For example, some α and β defensins, CAMPs 
present in human skin, are chemotactic for T lymphocytes, monocytes and 
immature dendritic cells. In vivo studies showed that some CAMPs, like LL-37, 
stimulate macrophages to produces chemokines which in turn attract additional 
cells to the inflamed sites [13]. Several CAMPs protect the host against potentially 
lethal effects resulting from an excessive TLR-mediated inflammatory response 
induced by lipopolysaccharide (LPS) and other bacterial “endotoxin” by altering 
gene expression of various inflammatory cells [14]. The endotoxin-neutralizing 
activities is typical of many well-known CAMPs (LL-37, PR-39) [15] but is also found 
in recently identified CAMPs, like the thrombin-derived peptide which exerts 
immunomodulatory functions by inhibiting macrophage responses to bacterial 
lipopolysaccharide [10-16]. Thus, CAMPs can be considered as a bridge between 
innate and adaptive immunity.  
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Finally CAMPs promote wound healing [15]. Wound healing requires an 
orchestrated integration of complex cellular events involving hemostasis, 
inflammation, remodeling, angiogenesis, tissue formation and re-epithelialization 
[13]. Some CAMPs strongly expressed in skin epithelium during wound healing, like 
cathelicidins (e.g. LL-37), are involved in all phases of tissue repair including 
angiogenesis [13-17-18]. Interestingly, Ramos et al. demonstrated in vivo that 
antimicrobial peptide, LL-37, can be used topically to stimulate wound healing in a 
diabetic mice model [15]. 
Also some AAMPs show additional biological activities. For example, the structure 
of SAAPs present in pulmonary surfactant is similar to the charge-neutralizing pro-
peptides of Group I serine proteases. In particular, it has been demonstrated that 
they are trypsin inhibitors [19]. Therefore, SAAPs can regulate the activity of 
pulmonary proteases. 
These findings suggest that the potential pharmacological applications of AMPs are 
not limited to antibacterial therapy but include stimulation of immune system, tissue 
repair and wound healing. 
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1.4 Biotechnological application of AMPs 
AMPs biotechnological applications span from pharmaceutical industry to 
food industry. They are gaining attention mainly as antimicrobial alternatives, food 
preservatives and recently as immune defense regulators. Some AMPs, are 
already in phase II/III clinical trial as antimicrobials restricted to topical applications 
[4-14]. 
For anti-infective purposes, the first AMPs to be commercially manufactured were 
gramicidins produced by Bacillus brevis [20] used as antibiotics for topical 
applications. Other examples are nisin, approved since 1969 [21], and lactoferrin 
added to infant milk formula [22], both used in food industry as natural 
preservatives or dietary supplements. Currently, application of antimicrobial 
peptides in the medical field is still one of the most interesting perspective. The 
ability of AMPs to modulate the innate immune system has made them promising 
candidates also as vaccine adjuvants [14]. The inclusion of appropriate adjuvants 
in vaccines helps to improve their efficacy. Evidences are based on several 
observations such as human neutrophil defensins that can enhance both humoral 
and cell-mediated antigen- specific immune response in murine models [23]. 
Moreover, using natural peptides as templates, synthetic peptides have been 
designed that retain the immunomodulatory properties but lack unwanted effects 
like mast cell degranulation exerted by certain natural AMPs as the bovine peptide 
bactenecin. The resulting molecules, named IDR peptides (Innate Defense 
Regulators) boost protective immunity against infections without possessing direct 
antimicrobial action [24]. Nowadays many IDR-peptides are in clinical trial for 
topical application. An example is IMX-492 that has recently completed phase I 
clinical trials in patients with cancer chemotherapy-induced immune suppression 
[4-14]. Other peptides, such as MX-226 and Hlf1-11, were originally developed as 
antimicrobial peptides but later showed interesting immunomodulatory activities [4]. 
Thus, there are ample opportunities to develop AMPs for clinic use as anti-infective 
agents. 
 
1.5 Pharmacological potential of AMP mixtures 
Different classes of AMPs can cooperate to optimize bacterial killing. Metal 
scavengers (AAMPs and HAMPs) can slow down bacterial growth by subtracting 
essential nutrients. Membrane damaging peptides (CAMPs, AAMPs and HAMPs) 
can directly kill bacteria but also facilitate the penetration of AMPs that bind 
intracellular targets. AAMPs with protease inhibition activity can extend the life of 
AMPs and exert anti-inflammatory activity. LPS-binding CAMPs can both directly 
damage the outer membrane and act as LPS scavengers with anti-inflammatory 
activity. 
Not surprisingly all body fluids contain complex mixtures of different AMPs. Blood 
contains defensins, His-rich glycoprotein, several CAMPs and AAMPs derived from 
platelets and an undefined number of AMP-releasing proteins (e.g. thrombin, 
fibrinogen, apolipoproteins and, likely, many others). Skin constitutively produces 
dermcidin and psoriasin (two AAMPs) and in an inducible manner defensins and 
cathelicidins (CAMPs). The surfactant of airways contains both AAMPs and 
CAMPs. 
The pharmacological potential of AMPs and especially of AMP mixtures is obvious. 
These peptides could be used to integrate and potentiate conventional antibiotics 
when these molecules are ineffective due to the development of multidrug resistant 
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strains or the formation of biofilm. At the same time, they would provide anti-
inflammatory, wound healing and immunomodulatory activities. 
However, the use of peptides as drugs is hampered by the high production costs. 
Usually a peptide (or a protein) is used as a drug only when a conventional drug is 
not available or the peptide is significantly better than the drug from the 
pharmacological point of view. On the other hand, the costs of a pharmaceutical 
formulation including two or more peptides separately produced would be so high 
that even a very interesting pharmacological activity would not compensate for the 
effort needed to prepare the mixture. 
Only in the case of a peptide mixture prepared from the cleavage of a single 
precursor protein the costs could be adequate to hypothesize a scale up to the 
industrial level. Several results described in literature suggest that it is possible to 
project a “modular” artificial precursor protein whose cleavage would provide the 
desired mixture of biologically active peptides.   
 
1.6 Strategies for production of AMPs and AMP mixtures 
Chemical synthesis and biological production methods are the most popular 
techniques for production of peptides. 
Chemical synthesis is particularly well suited when a relatively small amount of 
peptide is required and when the peptide is shorter than about 30 residues [25]. 
However, as the biotechnological application of these molecules cannot overlook 
production costs, biological production methods can be potentially more attractive 
for large scale production. 
E. coli is a common microbial platform for AMPs production [26-27] due to its well-
known biology, for the availability of cloning vectors and cheap media for cell 
growth.  
The main concerns in developing an AMP production platform using bacterial 
expression systems are: (i) AMP toxicity for the host, ii) AMP intracellular 
degradation by proteases leading to low yields and iii) peptide purification. 
These difficulties can be circumvented by fusing the desired peptides to a carrier 
protein that can protect peptides from proteases, neutralize possible toxic effects 
and provide a convenient system for their purification. 
By now, more than 30 kinds of fusion tags with different sizes and functions have 
been used for AMPs expression. Some examples are: thioredoxin (Trx), 
glutathione S-transferase (GST), maltose binding protein (MBP), intein-mediated 
systems [28]. 
However, also fusion protein strategy has two main drawbacks. First, the fusion 
protein must be cleaved and the peptide needs to be separated from the carrier. 
Second, the desired peptide usually represents just a small percentage of the 
purified fusion protein. As for the cleavage of the peptide, it can be released from 
the fusion protein by enzymatic or chemical cleavage at a site suitably introduced 
at the carrier-peptide junction [27]. The efficiency and specificity of the cleavage is 
the main bottleneck of fused peptide production. Usually enzymatic proteolysis 
by factor Xa [29-30], enterokinase [31] and thrombin [32-33], the most used 
enzymes, is less efficient than chemical cleavage [34]. On the other hand, the most 
popular cleavage reagents, like cyanogen bromide (CNBr), formic acid and 
hydroxylamine, [34], often produce unwanted cleavages and side-chain 
modifications due to the harsh reaction conditions needed for the cleavage [34]. 
In the laboratory where this PhD project has been developed a method for the 
production of recombinant AMPs has already been optimized [35]. AMPs are 
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expressed as fusion proteins by attaching the desired peptide to the C-terminus of 
onconase (ONC) a frog ribonuclease from Rana pipiens [36]. ONC is a very well 
suited  carrier for several reasons: (i) it can be expressed at very high levels in 
inclusion bodies (about 200-250 mg/L in Terrific Broth); (ii) usually, no soluble ONC 
can be detected in cultures thus minimizing the risk of toxic effects of the ONC-
peptide  fusion proteins; (iii) it is a very small protein (104 aa) thus allowing high 
yields of the peptides after the cleavage; (iv) the solubility of denatured onconase 
is pH  dependent – the denatured protein is soluble only at pH <4 – thus allowing 
the purification of peptides soluble at pH 7 by selective precipitation of the carrier. 
Moreover,ONC does not contain Asp-Pro and Asn-Gly sequences and the mutant 
(M23L)-ONC [37] does not contain internal methionine residues, therefore 
onconase carrier will not be cleaved by all common chemical cleavage strategies 
such as  formic acid, which cleaves the bond between aspartate and proline, 
cyanogen bromide, which cleaves Met-X bonds and hydroxylamine, which cleaves 
the bond between asparagine and glycine [38]. In order to improve its efficiency as 
a carrier (M23L)-ONC was further engineered by site directed mutagenesis. All the 
aspartate residues were changed to glutamate as, even if at very low frequency, all 
the Asp-X sequences undergo cleavage in acidic conditions. These cleavage 
events would cause the release of undesired ONC derived fragments thus making 
more complex the purification of the AMP. The eight cysteine residues in (M23L)-
ONC were mutated to hydrophobic residues (leucine, isoleucine or tyrosine) to 
avoid the formation of undesired oxidation products during the purification. A His6 
tag was added at the C-terminus of ONC thus allowing the purification of the fusion 
protein by metal chelate affinity chromatography. The final carrier has been named 
ONC-DCless-H6. 
We tested the efficiency of our strategy by producing GKY20, a short cationic 
antimicrobial peptide derived from the C-terminus of human thrombin [16] active on 
different strains of E. coli with a minimal inhibitory concentration (MIC) lower than 
10 μM. Peptide GKY20, was fused to ONC-DCless-H6 through  a linker sequence 
ending with the acid cleavable aspartyl-prolyl sequence (Fig. 1.4). The recombinant 
peptide (P)GKY20 was purified according to the strategy shown in Figure 1.4 with 
a final purity of about 96% and a yield of about 15 mg per L of culture. The method 
has been already used to prepare three further cryptic CAMPs, from human 
apolipoproteins E and B, with lengths of 18, 25 and 37 residues [39-40]. All these 
peptides were obtained with yields higher than 10 mg/L of culture thus 
demonstrating the general applicability of the method. 
Even if efficient this method could be further optimized. In fact, if a 20-residue long 
peptide is produced from a precursor of about 130 residues, after the cleavage 110 
residues out of 130 are discharged. Higher yields could be obtained by appending 
to ONC more AMP “modules”, either identical or even different as in the schemes 
below: 
 
ONC-DCless-H6-(X-CAMP)n 
 
ONC-DCless-H6-X-CAMP1-X-CAMP2 
 
ONC-DCless-H6-X-CAMP1-X-CAMP2-X-CAMP3 
 
where X is a suited cleavage sequence (e.g. Asp-Pro, Met, Asn-Gly etc.) and “n” the 
number of repeats. CAMP1, CAMP2 and CAMP3 are different CAMPs which would 
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be obtained as a mixture after the cleavage of the precursor and selective 
precipitation of the carrier.  
On the other hand, J. H. Lee and coworkers [41] conceived an alternative strategy 
not based on the use of a carrier protein to prepare buforin II, a cryptic CAMP 
deriving from histone H2A. Initially they prepared head to tail multimers of buforin 
alone (from 2 to 6 repeats). These multimers showed very low expression levels. 
Moreover, expression levels decreased by increasing the number of repeats. These 
results were attributed by the authors to the toxicity generated by the very high 
positive charge of the multimers, indeed each buforin module has an net charge = 
+7 so that the (buforin II)6 multimer, 120 residues long, has a net charge = +42. 
Thus, an alternative strategy was used, based on the natural secretion system of 
another type of CAMP, magainins. These are frog CAMPs, present at high 
concentration in skin secretions. They are produced as large precursors containing 
several magainin copies separated by repeats of an acidic module called MIS 
(Magainin Intervening Sequences). After secretion, proteases cleave the precursor 
releasing the magainin modules [42]. Thus, Lee and coworkers designed a 
“modified MIS” (MMIS) and prepared a modular protein composed by alternating 
copies of MMIS and buforin II: 
 
(MMIS-M-buforin II-M-)n 
 
where n = 2-6 and M are methionine residues necessary to cleave the precursor by 
CNBr. It is worth to note that the MMIS modules had the same length and charge 
density of buforin. Thus each repeat MMIS-M-buforin II-M was globally neutral. 
Differently from buforin II multimers the new modular proteins were expressed at 
very high levels in inclusion bodies. 
 
We decided to use a modified Lee’s strategy using as neutralization acidic peptide 
an AAMP i.e. a peptide endowed itself with a antimicrobial activity and able to 
contribute to the pharmacological activity of the mixture after the cleavage of the 
precursor. 
The general structure of such a precursor can be described by the scheme: 
 
(AAMP-X-CAMP-X-)n 
 
where X is a suited cleavage sequence and “n”, the number of repeats. 
Once cleaved, these artificial fusion proteins would immediately provide a mixture of 
CAMPs and AAMPs whose pharmacological applications could be wider than those 
of the single AMPs. 
In principle it could also be possible to design precursor containing two or more 
different CAMP modules and two or more different AAMP modules as well as to 
insert further functional peptides like for example histidine-rich or proline-rich AMPs. 
Moreover, if necessary, these modular precursors could also be attached at the C-
terminus of carriers like ONC-DCless-H6 to increase expression levels: 
 
ONC-DCless-H6-(X-AAMP-X-CAMP)n 
 
 
 
 
17  
 
 
 
 
 
 
 
 
                         
 
 
 
 
 
 
 
 
 
 
 
                          
 
Figure 1.4: Schematic representation of expression vector and recombinant protein. 
(from Pane K. et al. 2016). 
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1.7 Aims 
The general aim of this research work is the development of effective 
methods for the production of mixture of two or more recombinant AMPs with 
additive and/or synergistic activity that can be produced as a single precursor 
protein i.e. a mixture of AMPs that not only should be very interesting from the 
pharmacological point of view but that could be prepared in a single production line 
thus making the costs of production comparable to the costs of a single 
recombinant protein. 
 
This goal has been achieved through two tasks: 
 
I) Exploring the limits of the carrier-based method for the production of 
recombinant peptides by preparing fusion proteins bearing two or more AMP 
modules fused at the C-terminus of ONC-DCless-H6, according to the schemes:  
 
ONC-DCless-H6-X-CAMP1-X-CAMP2 
 
& 
 
ONC-DCless-H6-(X-AAMP-X-CAMP)n 
 
  
II) Preparing “carrier-less modular artificial precursors” that can be efficiently 
expressed in a bacterial host and successively cleaved to give an AMP mixture 
according to the scheme: 
(AAMP-X-CAMP-X-)n-TAG 
 
where “TAG” is a short tag sequence or an AMP that can be used as a tag 
sequence during the purification procedure. 
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2.1 Materials 
Expression host strain E.coli BL21(DE3) genotype: 95 F- ompT hsdSB (rB- 
mB - ) gal dcmrne  131  (DE3)  and  plasmid  pET22b(+)  were  purchased  from  
Novagen (San 
Diego, CA, USA). E. coli strain TOP10F’ was obtained from Invitrogen (San Diego, 
CA, USA). QIAprep spin miniprep kit was from Qiagen (Germantown, MD, USA). 
Wizard SV.Gel and PCR Clean-Up DNA Purification System for elution of DNA 
fragments from agarose gel was purchased from Promega (Madison, WI, USA). 
Enzymes and other reagents for DNA manipulation were from New England 
Biolabs (Ipswich, MA, USA). Ni Sepharose™ 6 Fast Flow was from GE Healthcare 
(Uppsala, Sweden). Yeast extract was from Becton-Dickenson (Franklin Lakes, 
NJ). Trypton was purchased from PanReac Applichem (Germany, UE). All other 
chemicals were from Sigma- Aldrich (Milano, Italy). 
 
2.2 General procedures 
Bacterial cultures, plasmid purifications and DNA manipulation were carried 
out according to Sambrook [43]. DNA sequences and oligonucleotide synthesis 
were performed by Eurofins MWG Operon service (Ebersberg, Germany). Sodium 
Dodecyl Sulphate PolyAcrylamide Gel Electrophoresis (SDS-PAGE) was carried 
out according to Laemmli [44]. The percentage of polyacrylamide was 6% for the  
stacking gel and 15% (to separate proteins with a molecular weight up to 10’000 
Da) or 20% (to separate peptides with molecular weight lower than 8’000 Da) in the 
resolving gel. Cleavage efficiency was analyzed by SDS-PAGE 20%. Gels were 
stained by Coomassie Blue staining solution containing 4% (v/v) formaldehyde to 
cross-link proteins and polypeptides [45]. Gallus gallus lysozyme (14.3 kDa) and 
colorburst electrophoresis marker (Sigma-Aldrich, St. Louis, MO, USA) were used 
as molecular marker. When appropriate, the relative amount of bands was 
determined by densitometry performed using the Gel Doc™ XR system (Bio-Rad 
Laboratories, Inc.) equipped with the Quantity One Software. Protein concentration 
were determined using the Bradford Protein Assay (Sigma-Aldrich, St. Louis, MO, 
USA) with standard curves generated using bovine serum albumin. Concentrations 
of purified fusion proteins and peptides were determined by spectrophotometric  
analysis using the extinction coefficients calculated using the ProtParam tool 
(accessible to the address http://web.expasy.org/protparam/). Alternatively, 
Bicinconinic acid Assay was used for peptides without aromatic residues. 
 
2.3 Synthetic coding sequences 
Synthetic DNA coding for the recombinant proteins described in “Results 
and discussion” section were obtained either from Eurofin Genomics (Ebersberg, 
Germany) or GenScript (Piscataway, USA). 
 
2.4 Bacterial growth culture media 
Luria Bertani Broth (LB) contained 1 % (w/v) sodium chloride, 1% (w/v) 
trypton and 
0.5 % (w/v) yeast extract. The solid medium was obtained from the liquid one by 
adding agar to a final concentration of 1.5% (w/v) as a gelling agent [43]. 
Terrific Broth (TB) was prepared with 1.2 % (w/v) trypton, 2.4 % (w/v) yeast 
extract; 
0.4 % (v/v) glycerol and potassium phosphate buffer 89 mM pH 7.4. 
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2.5 Antibiotics 
Ampicillin (Amp) was used always at a concentration of 100 g/mL. 
 
2.6 Expression of recombinant proteins 
E. coli strain BL21(DE3) was used to express all the recombinant proteins. 
Cells, transformed with pET recombinant plasmids were grown in 10 mL of TB 
medium containing 100 µg/ml ampicillin, at 37°C up to an absorbance of 2 OD at 
600 nm. These cultures were used to inoculate 1 L of TB/ampicillin medium 
supplemented  with 4 g/L glucose. Cultures were incubated at 37°C up to ODλ600nm 
of 3.5-4. Expression of recombinant proteins was induced by addition isopropyl-b-
D- thiogalactopyranoside (IPTG) at a final concentration of 0.4 mM. 
Cells were harvested after overnight induction by centrifugation at 8000x g for 15 
min at 4°C and washed with 50 mM Tris-HCl buffer, pH 7.4. The bacterial pellet 
was suspended in 100 mM Tris-HCl, pH 7.4, containing 20 mM EDTA, and 
sonicated in a cell disruptor (10 x 1 min cycle, on ice). The suspension was then 
centrifuged at 18,000 x g for 60 min at 4°C. Soluble and insoluble fractions were 
analyzed by SDS- PAGE. 
Only in the case of ONC-DCless-H6-(P)PAP-A3, ONC-DCless-H6-(P)PAP-
A3(Pro26) and ONC-AT2H the insoluble fractions containing the recombinant 
protein in the form of inclusion bodies were washed three times in 0.1 M Tris-HCl, 
pH 7.4, containing 10 mM EDTA, 2% Triton X-100 and 2 M urea, followed by 
repeated washes in 0.1 M Tris-HCl, pH 7.4, to eliminate traces of Triton, urea and 
EDTA. 
 
2.7 Purification of fusion proteins 
All the proteins were purified by immobilized metal ion affinity 
chromatography (IMAC), using the Ni Sepharose™ 6 Fast Flow resin. An amount 
of inclusion bodies corresponding to about 100 mg of fusion proteins were 
dissolved in 10 mL of denaturing buffer (5 M guanidine/HCl in 100 mM Tris-HCl, pH 
7.4) and incubated on a rotary shaker at 37°C for 3 h under nitrogen atmosphere. 
Soluble fractions were collected by centrifugation and incubated with 5 mL of Ni 
Sepharose™ 6 Fast Flow resin equilibrated in denaturing buffer. The resin was 
shaken at 4°C for 3 h and then collected by centrifugation. The supernatant, 
containing the unbound proteins, was discarded. The resin was washed three 
times with 25 ml of denaturing buffer at 4°C for 30 min and then packed in a glass 
column. Only in the case of ONC-AT2H, the resin was first packed in a glass 
column and then washed three times with 25 ml of denaturing buffer and 5 mM 
imidazole. The fusion proteins were eluted with 20 ml of 0.1 M sodium acetate 
buffer, pH 5.0, containing 5 M guanidine/HCl (elution buffer). The eluate was 
extensively dialyzed against 0.1 M acetic acid at 4°C. Purified fusion protein 
concentrations were determined by spectrophotometric analysis using theoretical  
extinction coefficients calculated using the ProtParam tool.  
 
2.8 Acid cleavage of Asp-Pro peptide bond 
Routinely acid cleavage of fusion proteins was performed in 0.1 M acetic 
acid buffered at pH 2.0 by addition of HCl for 24 h at 60°C in a water bath under 
nitrogen atmosphere. Percentage of cleaved protein was determined by 
densitometric analysis of SDS-PAGE gels as described in “General procedures”. 
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2.9 Purification of recombinant peptides 
After acid cleavage of the fusion proteins containing the carrier ONC-DCless-
H6, the pH of the peptide mixtures was adjusted to 7–7.2 by adding aqueous NH3. 
Samples were purged with N2 and incubated at 28°C for 16 h in a water bath. 
Soluble peptides were isolated from the insoluble carrier through repeated cycles of 
centrifugation at 18,000 x g for 60 min at 4°C. Purified peptides were lyophilized and 
stored at -80°C. Peptide concentrations were determined by spectrophotometrically 
using the theoretical extinction coefficients calculated using the ProtParam tool or by 
the BCA assay. Peptides derived from the cleavage of PAP-A3(Pro26) and ONC-
AT2H were purified by RP-HPLC as described in section 2.10. Purity of peptides 
was determined by SDS-PAGE and by RP-HPLC as described in section 2.10. 
 
2.10 RP-HPLC 
RP-HPLC (Reverse-phase high performance liquid chromatography) 
analyses were performed on a Jasco LC-4000 system equipped with PU-4086 semi-
preparative pumps and MD-4010 photo diode array detector. Jupiter 5µ C18 300Å 
column (250 x 4,6 mm, 5µm particle size) provided by Phenomenex was used for 
analytical chromatographies. Peptide purifications were carried out on Europa 
Protein 300 C18 column (5µm, 25 x 1mm) from Teknokroma. Solvents were 0.05% 
trifluoracetic acid (TFA) in water (solvent A) and 0.05% TFA in acetonitrile (solvent 
B).  
Pepsinogen and its fragments were analysed on the Jupiter 5µ C18 300A column by 
gradient 1 (5% solvent B for 10 min, 5-20% solvent B in 5 min, 20-30% solvent B in 
40 min, 30-40% solvent B in 5 min, 40-95% solvent B in 5 min). Elution profiles were 
recorded at 280 nm at a flow rate of 1 ml/min. 
(P)IMY25 and (P)FLK22 peptides were purified on the Europa Protein 300 C18 
column by gradient 2 (5% solvent B for 10 min, 5-20% solvent B in 5 min, 20-30% 
solvent B in 85 min, 30-95% solvent B in 1 min). Elution profiles were recorded at 
280 nm at a flow rate of 2 ml/min. 
Purified AT2H recombinant fusion protein and its hydrolysis pattern were analyzed 
on the Jupiter 5µ C18 300A column by gradient 3 (5% solvent B for 10 min, 5-30% 
solvent B in 5 min, 30-46% solvent B in 80 min, 46-100% solvent B in 5 min). Elution 
profiles were recorded at 230 nm at a flow rate of 1 ml/min. 
(P)GKY21, FibA and HRP peptides were purified on the Europa Protein 300 C18 
column by gradient 4 (5% solvent B for 10 min, 5-20% solvent B in 5 min, 20-36% 
solvent B in 85 min, 36-100% solvent B in 1 min). Elution profiles were recorded at 
230 nm at a flow rate of 2.5 ml/min. 
 
2.11 Antibacterial and antibiofilm assay 
Antibacterial activity assays were carried out by i) agar dilution plate viable-
count method [46] and ii) by broth microdilution method to determine the Minimal 
Inhibitory Concentration (MIC) with the collaboration of Dr. Katia Pane (Department 
of Biology, University of Naples, Frederico II) [47]. The minimal inhibitory 
concentration was defined as the lowest concentration completely inhibiting cell 
growth. Routinely assays were performed in Nutrient broth 0.5X.  
i) E. coli strain ATCC25922 was used in the antibacterial tests. The bacteria were 
grown for 3 h, diluted 1 : 1000 in 10 mM MOPS  buffer (pH 6.9), and incubated with 
increasing concentrations of peptides mixture at a density of 4.4x107 colony-
forming units (CFUs) in 1 mL. After 2 h at 37 °C, serial dilutions of each protein–
bacteria mix were prepared and plated, and CFUs remaining after each treatment 
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were determined. For each experiment, triplicate assays were performed.  
ii) Assays were carried out in Difco Nutrient Broth composed of 0.5% beef extract 
(w/v), 
0.05% pepton and 0.25% NaCl, using sterile 96-well polypropylene microtiter plates 
(cat. 3879, Costar Corp., Cambridge, MA). Twofold serial dilutions of peptides were 
carried out in the test wells to obtain concentrations ranging from 100 μM to 0.2 μM. 
Bacteria were inoculated from an overnight culture at a final concentration of ~ 
5x105 CFU/mL per well and incubated overnight at 37°C. MIC value was taken as 
the lowest concentration at which growth was inhibited. Three independent 
experiments were performed for each MIC value.  
Antibiofilm assays were performed in collaboration with the groups of Dr. Eliana De 
Gregorio and Prof. Maria Rosaria Catania (Dipartimento di Medicina molecolare e 
Biotecnologie mediche, Università degli Studi di Napoli Federico II). 
Antibiofilm activity was measured by crystal violet staining of adherent biofilm in 
BM2 minimal medium in 96-well plates to obtain the Minimal Biofilm Inhibitory 
Concentrations leading to 50% (MBIC50) or 100% (MBIC100) decrease in static 
biofilm growth. 
 
2.12 Bacterial strains used for antimicrobial susceptibility test 
Strains included Escherichia coli ATCC35218, Enterococcus faecalis 
ATCC29212, Acinetobatcer baumanii ATCC17878, Klebsiella pneumoniae ATCC 
700603, Escherichia coli ATCC25922 (kindly provided by Dr. Eliana De Gregorio, 
University of Naples, Federico II), Salmonella enterica serovar typhimurium 
ATCC14028, Salmonella enteriditis 706 RIVM (kindly provided by Dr. Edwin 
Veldhuizen, University of Utrecht, Holland), Pseudomonas aeruginosa PAO1 wild 
type (kindly provided by Dr. Donatella de Pascale, CNR, Naples), Staphylococcus 
aureus MRSA clinical isolate, Bacillus subtilis subp. spizizenii ATCC6633, 
Pseudomonas aeruginosa ATCC27853, Bacillus spizizenii ATCC6633 (kindly 
provided by Dr. Edwin Veldhuizen, University of Utrecht, Holland). 
 
2.13 Mass Spectrometry 
Mass spectrometry analyses were performed on a MALDI micro MX™, 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometer 
(MALDI-TOF MS), (Waters, Milford, MA USA).  
For MALDI-TOF analysis, 1 µL of digestion mixtures or each peptide solution was 
mixed with 1 µL of saturated α-cyano-4-hydroxycinnamic acid matrix solution [10 
mg/mL in acetonitrile:0.1% TFA (1:1; v/v)]. Thus, a droplet of the resulting mixture 
(1 µL) was placed on the mass spectrometer’s sample target and dried at room 
temperature. Once the liquid was completely evaporated, samples were loaded 
into the mass spectrometer and analysed. The instrument was externally calibrated 
using a tryptic alcohol dehydrogenase digest (Waters, Manchester, UK) in 
reflectron mode. For linear mode, a four-point external calibration was applied 
using an appropriate mixture (10 pmol/mL) of insulin, cytochrome C, horse Mb and 
trypsinogen as standard proteins (Sigma). A mass accuracy near to the nominal 
(50 and 300 ppm in reflectron and linear modes, respectively), was achieved for 
each standard. 
All spectra were processed and analysed using MassLynx 4.1 software [48]. 
 
  
  
 
 
 
 
 
 
 
Chapter 3-Results and Discussion 
  
26  
3.1 Production of CAMPS derived from the activation peptide of human 
pepsinogen. 
In order to verify the possibility to prepare ONC based fusion proteins 
bearing more than one CAMP module, the activation peptide of isoform A3 of 
human pepsinogen (PAP-A3) was selected as test CAMP. Pepsinogen is the 
precursor of pepsin, the main protease of gastric juice. With respect to pepsin it 
contains at the N-terminus an additional sequence of 47 residues, the so-called 
activation peptide, which is essential for pepsinogen storage in the secretory 
granules and for secretion process. Once pepsinogen is secreted in the gastric 
lumen, pepsin itself remove the activation peptide by a single cleavage between 
residue 47 and 48 of pepsinogen. According to literature, once released, activation 
peptide has no other physiological role. However, the activation peptide has been 
identified as a potential CAMP by a novel bioinformatic tool allowing the 
identification of cryptic antimicrobial peptides developed by our research group 
and recently accepted for publication in Journal of Theoretical Biology [49]. As the 
activation peptide is 47 residues long, at the beginning of the present project it was 
the longest peptide selected for the expression as a fusion protein with the carrier 
ONC-DCless-H6. Furthermore, the bioinformatic tool also suggested the presence 
of two shorter putative CAMPs within the activation peptide, approximately 
corresponding to the first 20-24 and the last 22 residues of the peptide. 
Intriguingly, it has been reported that activation peptide is, at least in part, cleaved 
by pepsin itself between residues D25-F26 [50] thus releasing the two hypothetical 
short CAMPs. Therefore, PAP-A3 can be considered a natural example of CAMPs 
present in tandem in a precursor thus being an ideal candidate to verify the 
possibility to express and purify several AMPs starting from the same precursor. It 
should be noted that PAP-A3 already contains an aspartate residue exactly at the 
predicted boundary between the two modules (i.e. bond D25-F26). Therefore, by 
simply inserting a proline residue between residue D25 and residue F26 in the 
PAP-A3 sequence it is possible to obtain a precursor containing an acidic 
cleavage site (sequence LLKDPFLK) located at the boundary between the two 
hypothetical CAMP-like modules (Fig. 3.1).  
Accordingly, two recombinant fusion proteins, ONC-DCless-H6-(P)PAP-A3 and 
ONC-DCless-H6-(P)PAP-A3(Pro26) were prepared, which differ for the presence 
of an additional proline in the latter protein (Fig. 3.1). 
The acidic hydrolysis at 60°C of ONC-DCless-H6-(P)PAP-A3 should produce two 
main fragments, the onconase carrier and the recombinant activation peptide with 
an  additional proline at the N-terminus left by the acidic cleavage, herein called 
(P)PAP-A3. As also the sequence D25-F26, present in PAP-A3, could undergo 
acidic hydrolysis at very low efficiency, the two main fragments could possibly be 
contaminated by two minor fragments corresponding to the first 26 residues of 
(P)PAP-A3 [peptide (P)IMY25] and the last 22 residues of (P)PAP-A3 [peptide 
FLK22] (Fig. 3.1). On the other hand the acidic hydrolysis of ONC-DCless-H6-
(P)PAP-A3(Pro26) should produce three main fragments: (i) onconase, (ii) the first 
25 residues of PAP-A3 [i.e.  (P)IMY25] and (iii) the last 22 residue of PAP-A3 with 
an additional proline at the N-terminus [herein called (P)FLK22]. 
The desired open reading frames were prepared by a cassette mutagenesis 
strategy routinely used in our laboratory. Briefly, the synthetic sequences coding 
for (P)PAP-A3 and (P)PAP-A3(Pro26) peptides were obtained by MWG-Biotech 
AG (Ebersberg, Germany) and cloned into pET22b(+)/ONC-DCless-H6 vector 
coding for the optimized ONC carrier.  
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Figure 3.1. Natural and recombinant peptides derived from human pepsinogen A3 
activation peptide. A) Full length pepsinogen activation peptide and its two shorter peptides 
derived from cleavage of DF internal acid labile site (bold and underlined characters) into the acid 
stomach environment. B) Recombinant peptides derived from ONC-DCless-H6-(P)PAP-A3 fusion 
protein by cleavage of DP site into the protein linker region [(P)PAP-A3 peptide] and DF internal 
cleavage site [(P)IMY25 and FLK22 peptides]. C) Recombinant peptides derived from ONC-
DCless-H6-(P)PAP-A3(Pro26) fusion protein by cleavage of DP site into the protein linker region 
[(P)PAP-A3(Pro26) peptide] and DPF internal cleavage site [(P)IMY25 and (P)FLK22 peptides]. 
Internal cleavage sites were highlighted as bold and underlined characters. 
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The recombinant proteins were expressed in E. coli strain BL21(DE3) as inclusion 
bodies at very high levels (about 200-250 mg/L in Terrific broth) (Fig. 3.2). 
Purification by immobilized metal ion affinity chromatography (IMAC) followed by 
dialysis in acetic acid 0.1 M, allowed a recovery of about 95% of the fusion proteins 
with about 98% purity (Fig. 3.3). Release of peptides from recombinant proteins 
was obtained by chemical cleavage of DP sequences in acidic medium (pH 2). As 
shown by SDS-PAGE analysis (Fig. 3.4), after 24 h of incubation at 60°C, the DP 
sequence located into the linker region of both fusion proteins, was efficiently 
cleaved (about 95% efficiency). Peptides were purified from the carrier by selective 
precipitation of the carrier at pH 7.2, followed by repeated cycles of centrifugation. 
Peptides were recovered in the soluble fraction at neutral pH, whereas carriers 
were found in the insoluble fractions. Two peptide bands were observed from the 
cleavage of both recombinant proteins (Fig. 3.4). 
 
                                  
 
 
                                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Expression of recombinant proteins. SDS-PAGE (15%) analysis of fusion proteins. 
Lane 1: Gallus gallus lysozyme; lane 2-4: insoluble fractions after cell lysis of cultures expressing 
ONC-DCless-H6-(P)PAP-A3 and ONC-DCless-H6-(P)PAP-A3(Pro26) fusion proteins, respectively; 
lane 3-5: soluble fractions after cell lysis of cultures expressing ONC-DCless-H6-(P)PAP-A3 and ONC-
DCless-H6-(P)PAP-A3(Pro26) fusion proteins, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
  1      2      3      4      5       
14.3 kDa 
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Figure 3.3. Hydrolysis analyses of recombinant proteins. 
ONC-DCless-H6-(P)PAP-A3(Pro26) fusion protein; lane 1: Gallus gallus lysozyme (14.3 kDa), 
purified (P)PAP-A3 (5.792 kDa) and (P)IMY25 (3.111 kDa) peptides (acid cleavage pattern); lane 2: 
soluble fraction after neutralization at pH 7; lane 3: soluble fraction after neutralization at pH 7; lane 
4: insoluble fraction after neutralization at pH 7 (carrier protein and uncleaved fusion protein). Gels 
(20 %) were stained by Coomassie Brilliant Blue R-250 in the presence of 4% formaldehyde. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Hydrolysis pattern analyses of recombinant proteins by SDS-PAGE.  
ONC-DCless-H6-(P)PAP-A3(Pro26) fusion protein; lane 1: Gallus gallus lysozyme (14.3 kDa), purified 
(P)PAP-A3 (5.792 kDa) and (P)IMY25 (3.111 kDa) peptides; lane 2: purified fusion protein after 
dialysis; lane 3: acid cleavage pattern; lane 4: soluble fraction after neutralization at pH 7; lane 5: 
insoluble fraction after neutralization at pH 7 (carrier protein and uncleaved fusion protein). Gels (20 
%) were stained by Coomassie Brilliant Blue R-250 in the presence of 4% formaldehyde. 
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The two hydrolysis mixtures were analyzed by RP-HPLC (Fig. 3.5) and mass 
spectrometry (Fig. 3.6) which allowed to identify all the expected fragments. In the 
case of ONC-DCless-H6-(P)PAP-A3 the main peak in the HPLC chromatogram 
corresponded to (P)PAP-A3 whereas two small peaks eluting earlier showed mass 
values identical to those expected for peptides (P)IMY25 and FLK22 within the 
experimental error. From the densitometric analysis of the Coomassie stained gels 
and the relative areas of the peaks in the HPLC chromatogram it could be 
estimated that about 95% of the ONC-DCless-H6-(P)PAP-A3 fusion protein (Fig. 
3.1B) was cleaved at Asp-Pro site at the N-terminus of PAP-A3 and about 5% of 
the peptide was cleaved at Asp25-Phe26. These percentages are in agreement 
with the previously determined average cleavage frequencies of Asp-Pro and Asp-
X sequences and show that the desired peptide of 47 residues can be obtained 
with a minimal loss due to the fragmentation at the inner aspartate residue. 
In the case of ONC-DCless-H6-(P)PAP-A3(Pro26) the three expected peptides 
(P)PAP-A3(Pro26), (P)IMY25 and (P)FLK22 were identified. However, the 
quantitative analysis allowed to estimate that about 95% of the ONC-DCless-H6-
(P)PAP-A3(Pro26) fusion protein (Fig. 3.1B) was cleaved at Asp-Pro site at the N-
terminus of PAP-A3 and only about 80% of the peptide was further cleaved at the 
inner site Asp25-Pro26. The lower cleavage efficiency of Asp25-Pro26 site 
compared to the Asp-Pro sequence in the linker region is likely due to a higher 
steric hindrance of the surrounding sequences as shown in the alignment below: 
 
GTGDPIMY 
LLKDPFLK 
 
The presence of the flexible linker (GTG) upstream the Asp-Pro site at the N-
terminus is likely useful for a high efficient cleavage. 
In order to increase cleavage efficiency, the acidic cleavage was performed in the 
presence of denaturants or at temperatures higher than 60°C. Unfortunately, 
hydrolysis in the presence of 4 M guanidine did not improve the efficiency, 
whereas, hydrolysis carried out at 70°C for 24 h greatly increased cleavage 
efficiency but also yielded unwanted unspecific fragmentation of the carrier and/or 
of the peptides. Therefore, the previously optimized cleavage conditions (0.1 M 
acetic acid pH 2, at 60°C for 24 h) were routinely used. 
Peptides were purified by RP-HPLC with a recovery of about 70% (Fig. 3.7). Purity 
of peptides was found to be more than 95% as measured by RP-HPLC (Fig. 3.8). 
(P)PAP-A3 peptide was produced with a final yield of about 18-20 mg/L of culture, 
whereas the shorter fragments (P)IMY25 and (P)FLK22 were produced with a final 
yield of 7-8 mg/L of culture for each peptide. Therefore, in spite of the incomplete 
cleavage of the inner Asp-Pro our strategy proved to be suited for the combined 
production of the two recombinant peptides. 
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Figure 3.5. RP-HPLC analyses of peptide mixtures.  
Samples were analyzed after selective carrier precipitation at neutral pH on Jupiter 5u C18 300A 
column. A) Peptides derived from cleavage of ONC-DCLess-H6-(P)PAP-A3 fusion protein; peak c, 
(P)PAP-A3 full length peptide; peaks a and b, the two shorter peptides [(P)IMY25 and FLK22, 
respectively] derived from cleavage of DF acid labile internal site. B) Peptides derived from cleavage 
of ONC-DCLess-H6-(P)PAP-A3(Pro26) fusion protein; peak c’, (P)PAP-A3(Pro26) full length peptide; 
peaks a and b’, the two shorter peptides [(P)IMY25 and (P)FLK22, respectively] derived from 
cleavage of DPF acid labile internal site. Molecular weight of peptides determined by Mass 
spectrometry were reported on the chromatograms. C) Representation of all recombinant peptides 
and their theoretical molecular weights. 
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Figure 3.6. Mass spectrometry analysis.  
In the table shows the experimental weight of the peaks obtained by mass spectrometry. 
 
 
 
 
 
 
 
 
 
 
m/z
1000 1200 1400 1600 1800 2000 2200 2400 2600 2800 3000 3200 3400 3600 3800 4000 4200 4400 4600 4800
%
0
100
Picco 6 13012017  15 (0.499) Sb (15,10.00 ); Cm (2:20) TOF LD+ 
4.89e32796.22
2795.30
2750.96
1396.15
2797.14
2818.33
2819.18
2841.15
2856.75
2985.71
m/z
1000 1200 1400 1600 1800 2000 2200 2400 2600 2800 3000 3200 3400 3600 3800 4000 4200 4400 4600 4800
%
0
100
Picco 5 13012017  2 (0.066) Sb (15,10.00 ); Cm (2:11) TOF LD+ 
4.08e33112.89
2996.92
1554.57
1497.38
1555.54
2582.41
1566.11
2826.90
2682.68 2978.48
3114.35
3133.77
3135.40
3136.54
3155.87
3157.99
3171.49
3196.60
m/z
1000 1250 1500 1750 2000 2250 2500 2750 3000 3250 3500 3750 4000 4250 4500 4750 5000 5250 5500 5750 6000 6250 6500 6750
%
0
100
Picco 4 13012017  14 (0.466) Sm (Mn, 3x5.00); Sb (15,10.00 ); Cm (8:17) TOF LD+ 
1.31e35794.91
5779.53
5750.93
2896.60
2889.09
2996.36
5809.32
5937.27
(P)PAPA3 5794.9Da 
(P)IMY25 3112.3Da 
(P)FLK22 2796.2Da 
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Figure 3.7. Peptide purifications by RP-HPLC. 
Peptides were purified on Europa Protein 300 C18 column. A) Peptides derived from cleavage of 
ONC-DCLess-H6-(P)PAP-A3 fusion protein; peak c, (P)PAP-A3 full length peptide; peaks a and b, 
the two shorter peptides [(P)IMY25 and FLK22, respectively] derived from cleavage of DF acid labile 
internal site. B) Peptides derived from cleavage of ONC-DCLess-H6-(P)PAP-A3(Pro26) fusion 
protein; peak c’, (P)PAP-A3(Pro26) full length peptide; peaks a and b’, the two shorter peptides 
[(P)IMY25 and (P)FLK22, respectively] derived from cleavage of DPF acid labile internal site. 
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Figure 3.8. Purity analyses by RP-HPLC of recombinant peptides tested as CAMPs in this 
study. Samples were analyzed on Jupiter 5u C18 300A after RP-HPLC purification. A) Peaks a and 
b’, shorter peptides [(P)IMY22 and (P)FLK22, respectively] derived from cleavage of ONC-DCLess-
H6-(P)PAP-A3(Pro26) fusion protein; peak c, (P)PAP-A3 full length peptide derived from cleavage of 
ONC-DCLess-H6-(P)PAP-A3 fusion protein. B) Representation of recombinant peptides and their 
theoretical molecular weights.  
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3.2 Antimicrobial activity 
The antibacterial activity of peptides (P)PAP-A3, (P)IMY25 and (P)FLK22 
was determined on the planktonic form of several Gram negative and Gram 
positive bacteria using as positive control (P)GKY20, a well known cryptic CAMP 
deriving from the C-terminus of human thrombin. An equimolar mixture of 
(P)IMY25 and (P)FLK22 (1µM of mixture corresponds to 1µM of (P)IMY25 plus 
1µM of (P)FLK22), used to simulate a completely cleaved (P)PAP-A3(Pro26), was 
also assayed. As reported in Table 1 (P)PAP-A3 shows MIC values similar or even 
lower to those of the control peptide on all the strains except P. aeruginosa strains. 
As for the shorter fragments, only (P)IMY25 shows significant activity whereas 
(P)FLK22 is active only on two strains. Not surprisingly the mixture of (P)IMY25 
and (P)FLK22 has an activity comparable to that of (P)IMY25 alone. 
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  3.3 Antibiofilm assays 
Since several pathogenic bacteria form biofilm we also investigated whether 
pepsinogen A3 derived peptides could affect preformed biofilm. 
Biofilm is a community of cells embedded in a self-produced polymeric matrix. The 
extracellular matrix acts as a filter able to reduce the penetration of toxic 
molecules (like antibiotics and AMPs). Moreover, microbial cells growing in a 
biofilm are physiologically distinct from planktonic cells of the same organism and 
often are intrinsically more resistant to antimicrobials than planktonic cells. As a 
consequence, antimicrobial agents active on planktonic cells often are active on 
biofilms only at very high concentrations and sometimes are not active at all. The 
peculiar nature of a biofilm makes also difficult to study the effect of antimicrobial 
agents on the bacterial community. For example, an antimicrobial agent could kill 
the cells inside the biofilm without affecting the extracellular matrix and hence its 
macroscopic structure. On the contrary, other antimicrobial agents could induce 
the “disaggregation” of the cells without killing them (i.e. escape from the biofilm). 
In order to discriminate between these different effects we used confocal 
microscopy coupled with a live(green)/dead(red) fluorescent staining of the cells. 
Assays were performed in collaboration with the groups of Dr. Eliana De Gregorio 
and Prof. Maria Rosaria Catania (Dipartimento di Medicina molecolare e 
Biotecnologie mediche, Università degli Studi di Napoli Federico II) 
Figure 3.9 shows the effect of the three peptides on a biofilm of Staphylococcus 
aureus strain ATCC6538P grown in static conditions. As highlighted by the bright 
red color at 25-50 µM (P)IMY25 induce considerable cell killing. Confocal 
microscopy results were further confirmed by using a cell viability assay (Fig. 
3.10). Indeed, (P)IMY25 at 51 µM reduced cell viability by 80% compared to 
untreated cells. As observed for other antimicrobials this concentration is about 
20-50 times higher than the MIC value measured on the planktonic form of this 
strain. Peptide (P)FLK22, less active than (P)IMY25 on the planktonic form of this 
strain, at 50 µM shows only a modest antimicrobial activity. Surprisingly, (P)PAP-
A3, whose MIC value on the planktonic form is identical to that of (P)IMY25, does 
not kill the cells in the biofilm even at highest concentration assayed. On the other 
hand, at low concentrations (7-15 µM) the longer peptide seems to be able to 
induce eradication of the biofilm as evidenced by the less bright green labeling and 
the presence of black spots. The inability to kill the cells inside the biofilm matrix 
could be related to the considerably higher molecular weight of (P)PAP-A3 with 
respect to its fragments. As discussed above the extracellular matrix is a very 
complex network of polymers including (acidic) polysaccharides and nucleic acid 
which could form an impenetrable filter for large molecules. Moreover several 
agents able to induce the disaggregation of biofilm have been described. For 
example some polyamines interact with the acidic polyanions in the biofilm matrix 
thus influencing its structure and inducing cell detachment. The group of R. 
Hancock discovered that some peculiar very short CAMPs induce cell detachment 
entering into the cells and influencing the transcriptional activity, thus acting as 
true signal molecules. Both mechanism could explain the activity of (P)PAP-A3 
however, at the moment, we have not investigated the interaction of the peptide 
with polysaccharides and nucleic acids nor if the peptide can be cleaved to small 
fragment by bacterial proteases.  
It is more difficult to explain why at higher concentrations (P)PAP-A3 seems to 
lose this ability. A simple explanation could be an aggregation process at high 
concentrations. However, it could be speculated that if fragments of the peptide 
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act as signal molecules, different levels of this hypothetical signal could induce 
different end even opposite effects. 
Figure 3.11 shows the effect of (P)PAP-A3 and (P)IMY25 on a biofilm of 
Pseudomonas aeruginosa strain PAO1 grown in static conditions. The 
characterization of (P)FLK22, on this strain is still ongoing. Surprisingly, (P)PAP-
A3 has no effect on the biofilm of this strain whereas (P)IMY25 induce a strong 
disaggregation of the biofilm when added at concentrations lower than 50 µM. It 
should be remembered that Pseudomonas aeruginosa PAO1 (a Gram negative) 
and Staphylococcus aureus ATCC6538P (a Gram positive) are very distant strains 
and both the chemical nature of their extracellular matrix and their ability to 
respond to signal molecules could be very different. 
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Figure 3.9. Confocal microscopy images of S. aureus ATCC 6538P static biofilm growth and 
eradication mediated by pepsinogen A3 derived peptides. 
Images represents live cells stained with Syto-9 (green) whereas dead cells stained with Propidium 
Iodide (red). The panels show representative results of at least two independent experiments. 
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Figure 3.10. Cell viability assay on S. aureus ATCC6538P by XTT colorimetric assay. 
Cell viability was evaluated following static biofilm growth in glass chambers and peptides treatment. 
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Figure 3.11. Confocal microscopy images of PAO1 static biofilm growth and eradication 
mediated by pepsinogen A3 derived peptides. 
Images represents live cells stained with Syto-9 (green) whereas dead cells stained with Propidium 
Iodide (red). At 25 and 50 µM (P)IMY25 induced a significant reduction of the biofilm even if no 
dead (red) cells were observed thus indicating that it acts through the induction of detachment 
rather than by killing the cells. The panels show representative results of at least two independent 
experiments. 
 
    
 
 
 
 
 
 
 
 
 
 
 
(P)IMY25 0 µM  (P)IMY25 100 µM (P)IMY25 50 µM (P)IMY25 25 µM 
(P)PAP A3 0 µM  (P)PAP A3 13,7 µM  (P)PAP A3 6,8 µM  (P)PAP A3 27,5  µM  
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3.4 Designing of a carrier-less modular artificial precursor 
The second objective of this PhD project is the optimization of the strategy 
initially developed by J. H. Lee [41] and described in the Introduction section. This 
requires the design of a modular artificial precursor containing alternate AAMP and 
CAMP modules which neutralize each other thus determining the formation of 
inclusion bodies or aggregates not harmful for the host. Such a precursor can be 
described by the general formula: 
 
(AAMP-DP-CAMP-DP-)n-TAG 
 
where “TAG” is a short tag allowing an easy purification of the precursor and DP are 
the acid labile sequences necessary for the cleavage of the precursor. 
The success of this strategy requires a careful choice of the three type of modules. 
In particular the AAMP and the CAMP modules should have similar length and net 
charge so that each AAMP-DP-CAMP-DP unit is uncharged. 
Among the possible CAMPs two promising candidates: GKY20, a CAMP derived 
from the C-terminus of human thrombin (20 aa; charge = +5) and ApoE-AP a CAMP 
derived from an internal domain of apoliprotein E (18 aa; charge = +8) were 
selected. Both peptides have been expressed in our laboratory as ONC-DCless-H6 
fusion proteins and purified with final yields of about 10-15 mg/L of culture and purity 
higher than 98%. Both GKY20 and ApoE-AP show high bactericidal activity on P. 
aeruginosa and S. aureus. Moreover, the two CAMPs can bind LPS and show anti-
inflammatory activity. 
Among the AAMPs described in literature, possible candidates were the 
fibrinopeptides A and B, the three SAAPs, dermcidin and thymosin-b4 (a platelet 
protein). On the basis of their chemical-physical features we selected fibrinopeptide 
A, FibA, as its length and charge density (16 aa; charge = -3;) are comparable to 
those of GKY20.  
Taking into account the two aspartate residues of the cleavage sites, the unit FibA-
DP-GKY20-DP has net charge = 0, therefore, this combination has been chosen for 
all the modular precursors. 
As for the TAG module, in principle a peptide able both to perform the role of tag 
sequence during purification and to contribute to antimicrobial activity of the mixture 
after the cleavage of the precursor would be particularly useful. Histidine rich 
antimicrobial peptides could fulfill this double role acting as tag sequences for the 
Immobilized Metal Affinity Chromatography (IMAC). Interesting candidates are 
histatins (zinc/copper binding antimicrobial peptides) and fragments of His-rich 
glycoprotein (His-GP). This large protein, present in the plasma of all vertebrates, 
contains an unstructured domain rich in histidines. For example, human His-GP 
contains several tandem repeats of the sequence HXHXH. It has been 
demonstrated that a 20 aa fragment isolated from this region has strong 
antimicrobial activity at acidic pH or in the presence of Zn2+ (obviously both 
conditions provide a high positive charge to the peptide) [48]. On the other hand it 
has been shown that sequences containing the HXH motif bind to Ni-chelate 
chromatographic resins even more strongly that the conventional His6 tag. This 
suggests that modules derived from His-GP could also act as an efficient His-tag for 
the purification of the modular artificial precursors.  
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On the basis of the considerations reported above the first synthetic precursor, 
herein called AT5H, was designed: 
 
                               MKQDP-(FibA-DP-GKY20-DP)5-HRP 
 
Where HRP is a 22 residues region from human His-rich glycoprotein (22 aa; 
HPHGHHPHGHHPHGHHPHGHHP) . 
It should be noted that the five residues MKQDP were added at the N-terminus for 
two different reasons:  
1) it has been demonstrated that two or more A and C rich codons following ATG 
codon co-operate with ribosomal binding site to increase the efficiency of 
translation thus providing high expression levels. As Lys and Gln are coded by the 
codons AAA and CAA, respectively, the addition of the KQ dipeptide provides a 
way to insert an A/C rich sequence after the ATG start codon; 
2) as acid hydrolysis cleaves the bond between Asp and Pro internal FibA 
modules are released with an additional proline residue at the N-terminus. Without 
the sequence KQDP upstream the first FibA module, this module would be 
released in the form Met-FibA thus providing an heterogeneous mixture of FibA-
type peptides. 
All the DP sequences in AT5H have a flexible sequence, rich in small and/or coil-
preferring amino acids that could provide an efficient cleavage, at least on one 
side as shown below: 
 
MKQDPADSGE-(FibA) 
(FibA)-GGGVRDPGKYGF-(GKY20) 
(GKY20)-IQKVIDPADSGE-(FibA) 
(GKY20)-IQKVIDPHPHGH-(HRP) 
 
It should be noted that the complete acidic hydrolysis of AT5H should provide a 
mixture of four peptides: 
 
1. The tetrapeptide MKQD, deriving from the N-terminus. 
2. The HRP peptide with an additional proline at the N-terminus [herein called 
(P)HRP]. 
3. The FibA peptide with an additional proline at the N-terminus and an 
additional aspartate at the C-terminus [herein called (P)FibA(D)] 
4. The GKY20 peptide with an additional proline at the N-terminus and an 
additional aspartate at the C-terminus, herein called (P)GKY21 as an 
aspartate residue is naturally present in the human thrombin sequence and 
it has already been demonstrated that its presence or absence does not 
influence the antimicrobial activity of the thrombin derived AMP (i.e. GKY20 
and GKY21 have the same antimicrobial activity). 
The four peptide should be releases in the following molar ratios: 
 
MKQD : (P)HRP : (P)FibA(D) : (P)GKY21 = 1 : 1 : 5 : 5 
 
The synthetic gene coding for AT5H was designed with the assistance of the 
custom synthesis service of GenScript. Usually during the design of a synthetic 
coding sequence, the codon usage of the sequence is adapted to that of the host 
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organism to obtain high expression levels. However, in the case of the sequence 
coding for AT5H, the use of the optimal codon usage in each of the five units 
would imply the presence of five identical direct repeats. These repeats would not 
only make particularly difficult the preparation of the synthetic DNA but could 
negatively influence replication, transcription and translation. Therefore, a 
proprietary software developed by GenScript which allows to minimize direct and 
inverted repeats exploiting the degeneration of the genetic code was used (Fig. 
3.12). Obviously this made not possible to fully comply with the codon usage of E. 
coli. 
 
 
 
 
 
atgaaacaagacccggctgatagcggcgaaggcgactttctggctgaaggcggcggcgtg 
M  K  Q  D  P  A  D  S  G  E  G  D  F  L  A  E  G  G  G  V 
cgtgatccgggcaaatacggcttttatacgcatgtgtttcgtctgaaaaaatggattcag 
R  D  P  G  K  Y  G  F  Y  T  H  V  F  R  L  K  K  W  I  Q 
aaagttatcgatccggcggacagcggcgagggtgatttcctggcagaaggcggtggcgtt 
K  V  I  D  P  A  D  S  G  E  G  D  F  L  A  E  G  G  G  V 
cgtgacccgggcaaatatggtttttacacccacgtcttccgcctgaaaaaatggattcaa 
R  D  P  G  K  Y  G  F  Y  T  H  V  F  R  L  K  K  W  I  Q 
aaagtgatcgatccggcagactctggcgagggtgattttctggctgaaggtggcggtgtc 
K  V  I  D  P  A  D  S  G  E  G  D  F  L  A  E  G  G  G  V 
cgcgatccgggtaaatacggtttttacacgcatgtttttcgcctgaaaaaatggatccag 
R  D  P  G  K  Y  G  F  Y  T  H  V  F  R  L  K  K  W  I  Q 
aaagtcatcgatccggcggacagtggtgagggcgatttcctggccgaaggcggtggcgtg 
K  V  I  D  P  A  D  S  G  E  G  D  F  L  A  E  G  G  G  V 
cgcgatccgggtaaatatggcttttacacccacgtgttccgtctgaaaaaatggatccaa 
R  D  P  G  K  Y  G  F  Y  T  H  V  F  R  L  K  K  W  I  Q 
aaagttatcgatccggcagattctggtgagggcgattttctggccgaaggtggcggtgtt 
K  V  I  D  P  A  D  S  G  E  G  D  F  L  A  E  G  G  G  V 
cgtgatccgggtaaatatggtttctacacgcatgttttccgtctgaaaaaatggatacag 
R  D  P  G  K  Y  G  F  Y  T  H  V  F  R  L  K  K  W  I  Q 
aaagtgatcgatccgcatccgcacggtcatcatccgcacggtcatcatccgcatggtcat 
K  V  I  D  P  H  P  H  G  H  H  P  H  G  H  H  P  H  G  H 
catccgcacggtcatcatccgtaa 
H  P  H  G  H  H  P  - 
 
Figure 3.12. Genetic code of AT5H. 
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3.5 Expression and purification of AT5H 
Recombinant AT5H was expressed in E. coli BL21DE3 strain with a yield of 
about 15 mg/L in Terrific Broth (TB) rich medium (Fig. 3.13). After cell lysis, AT5H 
was found in the insoluble fraction, as expected. However, when this fraction was 
washed with 0.1M Tris-HCl, pH 7.4, buffer containing 2% TritonX-100, 2 M urea, 
and 10 mM EDTA, a routine treatment for cleaning of inclusion bodies of 
Onconase-CAMP fusion proteins, AT5H was recovered into the soluble fraction. 
This suggests that recombinant AT5H protein forms aggregates that are not true 
inclusion bodies or that AT5H inclusion bodies are less stable than those formed 
by onconase. After dialysis in different buffers, AT5H, differently from ONC derived 
carriers, was soluble at both pH values 3 and 7. In both case also the majority of 
E. coli contaminant proteins remained soluble. 
 
 
 
 
 
                                  
 
 
Figure 3.13: SDS-PAGE analysis of cultures expressing AT5H, AT4LH and ONC-AT2H. 
Analysis was performed on a 15% acrylamide gel. Lane 1: marker ladder; Lane 2: cell lysate of 
induced culture of AT5H 0.126 O.D; Lane 3: cell lysate of not induced culture of AT5H 0.126 O.D; 
Lane 4: cell lysate of induced culture of AT4LH 0.126 O.D; Lane 5: cell lysate of not induced culture 
of AT4LH 0.126 O.D; Lane 6: cell lysate of induced culture of ONC-DCless-H6- AT2H 0.126 O.D; 
Lane 7: cell lysate of not induced culture of ONC-DCless-H6- AT2H 0.126 O.D; Lane 8: cell lysate of 
induced culture of ONC-DCless-H6-(P)GKY20 0.126 O.D; Lane 9: cell lysate of not induced culture 
of ONC-DCless-H6-(P)GKY20 0.126 O.D.  
Molecular weights of the protein in the marker ladder were: 245 kDa, 180 kDa, 135 kDa, 100 kDa, 
75 kDa, 63 kDa, 48 kDa, 35 kDa, 25 kDa, 20 kDa, 17 kDa, 11 kDa. 
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As an alternative strategy for the purification the aggregates of AT5H were 
dissolved in guanidine-HCl denaturing buffer (pH 7.4) and loaded the solubilized 
material on a Ni-sepharose column. As expected, due to the presence of the HRP 
module, AT5H showed a good affinity for the Ni-sepharose phase. After elution 
about 95% of the total fusion protein with more than 95% purity. (Fig. 3.14) was 
recovered. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14. SDS-PAGE (15%) analysis of fusion proteins.  
Lane 1: Ladder marker; lane 2: insoluble fractions before IMAC purification; lane 3: flow through of 
IMAC; lane 4: purified fusion protein by IMAC.  
Molecular weights of the protein in the marker ladder were: 180 kDa, 135 kDa, 100 kDa, 75 kDa, 
63 kDa, 48 kDa, 25 kDa, 20 kDa, 17 kDa, 11 kDa. 
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Purified AT5H recombinant protein was then dialyzed against 0.1 M acetic acid 
and hydrolyzed at 60 °C, pH 2 for 24 h. SDS-PAGE analyses of the cleavage 
product indicated that chemical cleavage occurred with very high efficiency. In 
fact, no band was observed at the molecular weight expected for the unhydrolyzed 
protein. Moreover, about 80% of the hydrolyzed fragments were observed at the 
position expected for peptides ~20-residues long, whereas less than 20% of the 
hydrolyzed fragments were observed at the position expected for ~40-residues 
long peptides [likely a mixture of (P)FibA-DP-GKY21, (P)GKY20-DP-FibA and/or 
(P)GKY20-DP-HRP modules]. No other band was observed thus indicating an 
almost complete hydrolysis of all Asp-Pro sites (Fig. 3.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15. Lane1: purified fusion protein by IMAC; lane 2: acid cleavage pattern; lane 3: 
insoluble fraction after neutralization at pH 7; lane 4: soluble fraction after neutralization at pH 7; 
lane 5: ONC-DCless-H6-(P)GKY20; lane 6: ONC-DCless-H6-(P)PAP-A3 fusion protein. 
Gels (20 %) were stained by Coomassie Brilliant Blue R-250 in the presence of 4% formaldehyde. 
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3.6 Designing of a second carrier-less modular artificial precursor 
The expression levels of AT5H (about 15 mg/L of culture) could be 
considered acceptable taking into account that it is an entirely artificial protein but 
are very poor if compared to those of the several ONC-CAMP fusion proteins 
previously prepared in our laboratory (typically 150-250 mg/L depending on the 
CAMP). 
Possible causes of the low expression levels could be the non optimal codon 
usage –necessary to avoid the five identical direct repeats in the coding 
sequence– or the inability to form stable aggregate/inclusion bodies which would 
avoid the possible toxic effects on the host of the antimicrobial sequences in 
AT5H. 
On this basis we reconsidered our strategy. A second ORF coding for a new 
modular protein, herein called AT4LH, was designed. AT4LH contains four (FibA-
DP-GKY20-DP) modules instead of five as in AT5H. Moreover, the synthetic gene 
was designed with the assistance of the custom synthesis service of the “Eurofin 
Genomics” company that has developed a proprietary software for codon usage 
optimization different from that developed by the GenScript company used for 
AT5H. Moreover, the coding sequence was endowed with a Bam HI restriction 
site in the middle for subcloning the fragment coding for the two terminal (FibA-
DP-GKY20-DP) modules at the 3’ of the ONC-DCless-H6 ORF in the vector 
pET22/ONC-DCless-H6, thus providing a backup strategy in the case AT4LH was 
expressed at low levels. 
The schematic structure of the ORF coding for AT4LH is:   
 
(M)L1-(FibA-DP-GKY20-DP)2-L2-(FibA-DP-GKY20-DP)2-HRP(stop) 
|                                                 | |                                                        | 
NdeI                                    KpnI BamHI                                              SacI 
 
Where FibA, GKY20 and HRP modules code for the above described AMPs, L1 
codes for KQDP (the “adaptor” already present in AT5H) and L2 codes for a six 
residues sequence (GHGTKG) which allows to insert two restriction sites (KpnI 
and BamHI) which make possible the cloning of the 3’ half of the ORF at the C-
terminus of ONC. 
By cloning the entire ORF in the NdeI/SacI site of pET22b(+) vector we prepared 
vector pET22b/AT4LH allowing the expression of the carrierless modular protein 
AT4LH: 
 
MKQDP-(FibA-DP-GKY20-DP)2-L2-(FibA-DP-GKY20-DP)2-HRP 
 
The complete acidic hydrolysis of AT2LH should provide a mixture of five peptides 
in the following molar ratios: 
 
MKQD : (P)L2(D) : (P)HRP : (P)FibA(D) : (P)GKY21 = 1 : 1 : 1 : 4 : 4 
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3.7 Expression and purification of AT4LH 
The recombinant protein AT4LH was purified following the purification 
procedure already used for AT5H. 
AT4LH was expressed in E. coli BL21DE3 strain with a yield of about 30 mg/L, hence 
only slightly higher than AT5H. After cell lysis, AT4LH was found in the insoluble 
fraction, as expected. However, when this fraction was washed with 0.1M Tris-HCl, 
pH 7.4 buffer containing 2% TritonX-100, 2 M urea, and 10 mM EDTA, AT4LH was 
identified into the soluble fraction together with several E. coli proteins as previously 
observed for AT5H. In order to find an alternative washing buffer, AT4LH inclusion 
bodies were divided into two aliquots which were washed in denaturing buffer (pH 
7.4) containing guanidine-HCl at final concentrations of 0.5 and 1 M for 20h at room 
temperature. SDS-PAGE analyses showed that the buffers containing 0.5 M and 1M 
guanidine-HCl allowed to remove 10% and 40% of the contaminant E. coli proteins, 
respectively, without solubilizing AT4LH. The pellet obtained by centrifuging the 
inclusion bodies washed with the buffer containing 1 M guanidine-HCl were further 
washed with a buffer containing 1.5 M of guanidine-HCl. In this case SDS-PAGE 
analyses showed that 98% of the AT4LH was in the soluble fraction whereas the 
insoluble fraction contained essentially E. coli proteins. The solubilized AT4LH was 
further purified by immobilized metal ion affinity chromatography (IMAC). About 95% 
of AT4LH with more than 85% purity was recovered.  
Purified AT4LH recombinant protein was then dialyzed against 0.1 M acetic acid and 
hydrolyzed at 60 °C, pH 2 for 24 h. SDS-PAGE analyses of the hydrolyzate showed 
that AT4LH gives a fragmentation pattern essentially identical to that obtained in the 
case of AT5H (fig. 3.16). Final yield of the peptide mixture was about 6-7 mg/L of 
culture. 
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Figure 3.16: SDS-PAGE analysis of AT4LH hydrolysis products. Analysis was performed on a 
20% acrylamide gel. Lane 1: marker ladder; Lane 2: purified fusion protein AT4LH in acetic acid 0.1M; 
Lane 3: Acid cleavage of AT4LH;  
Molecular weights of the protein in the marker ladder were: 180 kDa, 135 kDa, 100 kDa, 75 kDa, 63 
kDa, 48 kDa, 25 kDa, 20 kDa, 17 kDa, 11 kDa. 
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3.8 Cloning, expression and purification of ONC-AT2H 
As also the carrier-less modular protein AT4LH provided unsatisfactory 
expression levels we decided to create a fusion protein between the carrier ONC-
DCless-H6 and the C-terminal half of the modular protein AT4LH. By cloning the 
BamHI/SacI fragment present at the 3’ of the ORF coding for AT4LH, described in 
section 3.6, into the vector pET22/ONC-DCless-H6 already available in our 
laboratory we prepared the expression vector named pET22/ONC-AT2H allowing 
the expression of the fusion protein ONC-AT2H: 
 
ONC-DCless-H6-DP-(FibA-DP-GKY20-DP)2-HRP 
 
It should be noted that five AMP modules are appended to the C-terminus of the 
ONC derived carrier and that the modular part has a length comparable to that of 
the carrier (103 and 120 residues respectively). 
The complete acidic hydrolysis of ONC-AT2H should provide a mixture of four 
peptides in the following molar ratios: 
 
ONC-DCless-H6 : (P)HRP : (P)FibA(D) : (P)GKY21 = 1 : 1 : 2 : 2 
 
Recombinant ONC-DP-AT2H was expressed in E. coli BL21DE3 strain with a yield of 
about 120 mg/L in Terrific Broth (TB) rich medium (Fig. 3.17a). After cell lysis, ONC-
AT2H was found in the insoluble fraction, as expected (Fig. 3.17b). When this fraction 
was washed with 0.1 M Tris-HCl, pH 7.4 buffer containing 2% TritonX-100, 2 M urea, 
and 10 mM EDTA, a routine treatment for cleaning inclusion bodies of onconase-
CAMP fusion proteins, ONC-AT2H was  found into the insoluble fraction thus 
confirming that an ONC module is necessary to obtain high insoluble inclusion 
bodies.  
By IMAC purification a recovery of about 95% of the total fusion protein with more 
than 95% purity was achieved. Purified ONC-AT2H was then dialyzed against 0.1 M 
acetic acid and hydrolyzed at 60 °C, pH 2 for 24 h. SDS-PAGE analyses (Fig. 3.18) 
of the cleavage product indicated that cleavage occurred at a very high efficiency: 
about 80% of the recombinant protein was cleaved to the expected peptides ~20-
residues long. In order to remove the onconase from the sample, a selective 
precipitation was performed by adjusting pH at 7.2 by addition of ammonia. About 15-
16 mg of the peptide mixture were obtained. HPLC and mass analysis allowed to 
confirm that the main products of the acid cleavage are the expected peptides (P-
ThrAP-D; P-FibA-D and P-HRP) and the ONC-D protein (Fig. 3.19 and Table 2). 
Comparing the results obtained from the two modular proteins, AT4LH and ONC-DP-
AT2H, it can be concluded that ONC-DP-AT2H provides higher yields with a simpler 
purification procedure. 
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Figure 3.17: Purification of peptides mixture. 15% SDS analysis.(A) Lane 1: marker ladder; Lane 
2: cell lysate of induced culture of ONC-DCless-H6- AT2H 0.126 O.D; Lane 3: cell lysate of 
analytical not induced culture of ONC-DCless-H6- AT2H 0.126 O.D; Lane 4: cell lysate of analytical 
induced culture of ONC-DCless-H6- AT2H 0.126 O.D. (B) Lane 1: marker ladder; Lane 2: cell lysate 
of induced culture of ONC-DCless-H6- AT2H; Lane 3: cell lysate of soluble fraction of ONC-DCless-
H6- AT2H; Lane 4: cell lysate of insoluble fraction of ONC-DCless-H6- AT2H. Molecular weights of 
the protein in the marker ladder were: 245 kDa, 180 kDa, 135 kDa, 100 kDa, 75 kDa, 63 kDa, 48 
kDa, 35 kDa, 25 kDa, 20 kDa, 17 kDa, 11 kDa. 
 
 
 
                                     
 
Figure 3.18: SDS-PAGE analysis of ONC-AT2H. Analysis was performed on a 20% acrylamide 
gel. Lane 1: marker ladder; Lane 2: purified ONC-AT2H in acetic acid 0.1M; Lane 3: Acid cleavage 
of ONC-AT2H; Lane 4: Insoluble fraction after neutralization at pH 7; Lane 5: Soluble fraction after 
neutralization at pH 7. Molecular weights of the protein in the marker ladder were: 245 kDa, 180 
kDa, 135 kDa, 100 kDa, 75 kDa, 63 kDa, 48 kDa, 35 kDa, 25 kDa, 20 kDa, 17 kDa, 11 kDa. 
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Figure 3.19: RP-HPLC analysis of hydrolyzed ONC-AT2H. 
Blue line, purified ONC-AT2H; pink line hydrolyzed ONC-AT2H. Absorbance was recorded at 230 nm. 
 
 
 
 
Peak Experimental weight 
([M+H]+) 
Theoretical weight 
([M+H]+) 
Sequence position 
Peak 1 2611.19 a 2612.76 195-217 (HRP) 
Peak 2 1748.75 a 1749.78 115-132/155-172 (FIBA) 
Peak 3 2723.46 a 2724.25 133-154/173-194(GKY21) 
Peak 4 13364b 13363 1-114 (ONC-DCless-H6) 
Peak 5 24848b,c 24831 1-217(ONC-DCless-H6-AT2H) 
 
a TOF reflectron mode. 
b
 TOF linear mode. 
c
 The observed difference between the theoretical and the experimental molecular weight (17 Da) may 
be caused by the oxidation of residue Met(-1) in the fusion protein. This oxidation has been observed 
in other fusion proteins containing ONC-DCless-H6 as a carrier. 
 
Table 2: Mass spectrometry analysis.  
In the table shows the theoretical and experimental weight of the peaks obtained by HPLC and 
analyzed by mass spectrometry. 
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3.9 Antimicrobial activity of AT2H 
In order to study the antimicrobial activity of the peptide mixture derived from 
the hydrolysis of ONC-AT2H, dose-effect curves were carried using (P)GKY20 as 
positive control. The activity of (P)GKY21 purified from the mixture by HPLC was 
also assayed. 
The comparison of the activities of a single AMP and a mixture of three AMPs is not 
trivial. As the mixture contains (P)GKY21 (which corresponds to 2/5 of the mixture 
on a molar basis) the concentration of the mixture was expressed as “molar 
equivalents” of peptide (P)GKY21. Thus, for example, 1 μM of mixture corresponds 
to 1 μM of (P)GKY21, 1 μM of (P)FibA(D) and 0.5 μM of (P)HRP. 
As shown by the curves in Fig. 3.20, (P)GKY20 and (P)GKY21 show essentially the 
same activity as expected from the literature data, whereas, the mixture containing 
also (P)FibA(D) and (P)HRP is considerably more active thus suggesting that these 
two AMPs contribute significantly to the antimicrobial activity of the mixture. At the 
moment it is not possible to determine the relative contribution of (P)FibA(D) and 
(P)HRP and if the activity of these peptide is additive or synergic with that of 
(P)GKY21. The answers to these questions will first require the purification of 
adequate quantities of (P)FibA(D) and (P)HRP. 
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Figure 3.20: Viable count assay of the peptide mixture from ONC-AT2H. 
Blue squares, GKY20; red triangles, GKY21; green circles, peptide mixture obtained by 
hydrolyzing ONC-AT2H. 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Chapter 4-Conclusions 
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The activities of the present PhD thesis have been carried out in the context 
of a wide research project whose main goal is the development of human AMPs-
based antimicrobial drugs for topic applications like treatment of surgical wounds, 
ulcers and skin, mouth and airways infections. The main aim of the project is the 
development of strategies and tools for the production of AMPs and in particular of 
production strategies allowing an easy scale up from the laboratory scale to the 
pilot and even the industrial scale. In this context our research group has already 
developed an optimized carrier (ONC-DCless-H6) for the production of 
recombinant AMPs as fusion proteins in E. coli. This method not only provides high 
amount of peptides with high purity but also involves relatively few purification 
steps, thus allowing to limit production costs. The specific aim of the present 
project is to further widen the applicability of our approach to the production of 
mixtures of two or more AMPs. The pharmacological potential of such mixtures is 
high but the cost and the complexity of production has discouraged, until now, their 
development. Therefore, a strategy to prepare mixtures of two or more AMPs with 
costs, production times and amount of work comparable to those necessary for the 
production of a single recombinant AMP would open the way to the exploitation of 
AMP mixtures. 
Two alternative strategies were evaluated, one still exploiting the previously 
optimized onconase-based carrier and an alternative strategy aiming to prepare 
carrier-less precursors composed only by AMP modules thus minimizing the 
production of “waste material”.  
The characterization of the proteins ONC-DCless-H6-(P)PAP-A3(Pro26) and ONC-
DCless-H6-AT2H has confirmed the excellent performances and the reliability of 
the carrier based method. ONC-DCless-H6 was able to effectively drive to inclusion 
bodies both a highly cationic sequence of about 50 residues containing two CAMP-
like sequences [(P)PAP-A3(Pro26)] and a modular sequence of more than 100 
residues including anionic, cationic and histidine rich modules (AT2H). In both 
cases the expression yields were high (>200 mg/L and >100 mg/L, respectively) 
and the purification by IMAC provided a protein with good yield and purity. 
As for the cleavage at the multiple junction sites, a crucial point of any strategy for 
the production of multiple peptides from a single precursor, acid cleavage in 0.1 M 
acetic acid at 60°C confirmed to be a reliable, easy and “green” strategy (not 
including organic solvents, toxic reagents or harsh condition). The efficiency was 
very high in the case ONC-DCless-H6-AT2H which essentially provided only the 
desired peptides, thus indicating that all the acid labile Asp-Pro sequences 
underwent cleavage with an efficiency likely higher than 95% (indeed incomplete 
cleavage products were not distinguishable from the background of the RP-HPLC 
chromatogram). After the acidic cleavage, the mixture was easily separated from 
the carrier by simply changing the pH to cause the aggregation of the carrier. The 
mixture of peptides which was obtained by our procedure contained only the 
desired peptides, and was used in biological assays to test their efficiency as 
antimicrobial agents without any further purification. In the perspective of a scale 
up of the production this is obviously a particularly advantageous feature. On the 
contrary, in the case of ONC-DCless-H6-(P)PAP-A3(Pro26), the internal Asp-Pro 
sequence was cleaved with an efficiency of only about 85%. Thus, after 
precipitation of the carrier, the mixture contained a significant amount (about 10% 
by weight) of the not-cleaved (P)PAP-A3(Pro26) peptide. The comparison of the 
sequences adjacent to the different Asp-Pro cleavage sites in ONC-DCless-H6-
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(P)PAP-A3(Pro26) and ONC-DCless-H6-AT2H suggested that in order to obtain a 
very high cleavage efficiency a flexible sequence, rich in small and/or coil-
preferring amino acids, should be present at least on one side of the Asp-Pro site. 
This information will be useful for the design of further fusion proteins.  
In the case of the carrier-less modular precursors the results were less positive but, 
nonetheless, they provided useful indications for a future optimization of this 
alternative strategy. Both modular proteins AT5H and AT4LH showed relatively low 
expression levels (15 and 30 mg/L, respectively) and the formation of inclusion 
bodies which, differently from those generated by ONC-DCless-H6, were soluble in 
2 M urea suggesting a lower compactness/stability. Possible causes of the low 
expression levels could be the non-optimal codon usage necessary to avoid the 
presence of 4-5 identical direct repeats in the coding sequences. The low 
expression levels, in turn, could contribute to the formation of the “unstable” 
inclusion bodies. Indeed, it is well known that inclusion bodies formation is 
generally related to high expression levels. It should be noted that alternatives to 
the direct chemical synthesis of repetitive DNA sequences are well described in 
literature. For example small DNA fragments can be joined by ligation to produce 
long sequences with variable number of identical direct repeats. In the future this 
kind of approach could allow preparing coding sequences where all the repeats 
have an optimal codon usage. 
In conclusion we believe that, even if not all the initial objectives have been fully 
achieved, this PhD work will pave the way to the development of pharmacologically 
interesting peptide mixtures.  
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5.1 Myxococcus xanthus 
Myxococcus xanthus is a soil bacterium which commonly grows in damp soil 
rich in organic matter (Fig. 5.1). The bacteria are rod shaped and 10 times bigger 
than E. coli in size, able to use peptides, lipids and other macromolecules for 
nutrition and tend to form large multicellular communities, which feed upon other 
microorganism, utilizing extracellular antibiotics and degradative enzyme to 
immobilize and digest their prey [52-53-54]. 
M. xanthus is one of many diverse Gram-negative bacteria which move by gliding 
motility. Gliding motility is generally described as the movement in the direction of 
the long axis of the cell at a solid-liquid, solid-air or air-liquid interface without the aid 
of flagella [55]. M. xanthus has two genetically distinct systems for motility. 
 The first system, known as social (S)-motility and involves the movement of cells in 
group [56]. The second one, known as adventurous (A)-motility and involves the 
movement of single cells.  
S-motility requires type IV pili, lipopolysaccharide (LPS) O-antigen, and extracellular 
matrix polysaccharide (called fibrils). Type IV pili are particularly determinant for S-
motility: it has been shown indeed that pili, extruded from one cell pole, adhere to 
the exopolysaccharide deposited on a surface or on another cell so that following 
retraction of the pilus, pulls the cell in the direction of the site of adhesion [57-58-59-
60].  
A- motility is not yet clarified so far. A commonly accepted hypothesis assumes the 
extrusion of a polyelectrolyte gel to push the cell forward [61]. A more recent model 
proposes that intracellular motor complexes, connected to both membrane-spanning 
adhesion complexes and to the cytoskeleton, enhance the motility by pushing cell 
body towards to the substratum, in a way similar to focal adhesion-based traction or 
apicomplexan gliding motility in eukaryotic organisms [62].  
M. xanhus cells periodically reverse their direction of movement and cell reversals 
are thought to be required for directional adjustment as part of the biased random 
walk necessary for chemotaxis. In nature, when M. xanthus swarming cells are 
unable to find sufficient nutrients, they enter a developmental process in which they 
aggregate forming raised pigmented mounds, termed fruiting bodies. Cells 
encapsulated inside fruiting bodies differentiate to form spores. Spores are 
metabolically dormant cells that can withstand prolonged periods of starvation, 
desiccation, and relatively high temperatures for their soil habitat. The process of 
sporulation involves the rounding up of the cells and the restructuring of the cell wall 
[53-54]. Although fruiting bodies involve the majority of cells (80-90%) aggregate to 
form fruiting bodies, some cells may follow a different developmental fate. It has 
been hypothesized that they could be scout cells, since spores cannot search for 
prey [63]. 
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Figure 5.1: Life cycle of Myxococcus xanthus.  
Myxococcus xanthus cells are usually found on solid substrates. When nutrients are present, groups 
of cells (swarms) grow and divide and move outward in search of additional macromolecules or prey. 
Upon starvation, cells aggregate at discrete foci to form mounds and then macroscopic fruiting 
bodies. The rod-shaped cells in the fruiting bodies undergo morphogenesis and form spherical 
spores that are metabolically inactive and partly resistant to desiccation and temperature. Peripheral 
rods remain outside fruiting bodies and move as accordion waves in their search for food. When 
nutrients become available, the spores germinate and complete the life cycle. [64] 
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5.2 Frz system 
The Frz chemosensory system controls directed motility in M. xanthus by 
regulating cellular reversal frequency. In contrast to E. coli, M. xanthus has eight 
chemotaxis-like pathways [65], four of which have been characterized [66-67-68-
69]. 
The Frz system was the first pathway to be studied and is responsible for 
controlling the frequency at which individual cells reverse their direction of 
movement (Fig. 5.2) [70-71-72]. M. xanthus requires the Frz system for vegetative 
swarming on rich media and for cellular aggregation during fruiting body formation 
on starvation media. In fact, directional control is required for cells to move in a 
biased random walk during colony swarming and for aggregation during fruiting 
body formation. The Frz system consists of: FrzCD, a cytoplasmic chemoreceptor; 
FrzA and FrzB, two CheW-like proteins (CheW domain is topologically similar to 
SH3 domains from eukaryotic scaffold proteins that also play a role in signal 
transduction [73-74]); FrzE, a CheA–CheY fusion protein; FrzF, a 
methyltransferase; FrzG, a methylesterase; and FrzZ, a CheY–CheY fusion protein 
[66-75]. These proteins share homology with chemotaxis proteins from enteric 
bacteria, which are encoded in the frzA-F operon and the divergently transcribed 
frzZ gene.  
Mutants containing transposon or plasmid insertions in the frz genes rarely reverse 
their direction of gliding and are defective in swarming [72]. Furthermore, frz 
mutants are unable to form fruiting bodies when starved but at the contrary tend to 
aggregate into tangled filaments evolving in a phenotype termed ‘frizzy’ [70-72-76].  
FrzCD, the Frz chemoreceptor, contains a conserved C-terminal module present in 
methyl-accepting chemotaxis proteins (MCPs); but, in contrast to most MCPs, 
FrzCD is localized in the cytoplasm and the N-terminal region of FrzCD does not 
contain transmembrane or sensing domains, or even a linker region.  
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Figure 5.2: The Frz system.  
The Frz system consists of: FrzCD, a cytoplasmic chemoreceptor; FrzA and FrzB, two CheW-like 
proteins; FrzE, a CheA–CheY fusion protein; FrzF, a methyltransferase; FrzG, a methylesterase; and 
FrzZ, a CheY–CheY fusion protein [16]. 
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5.3 Construction of a ∆frzA ∆frzB frzBAβ4β5 strain producing the FrzBAβ4β5 
Chimera  
Frz system (see Figure 5.2) has two CheW-like proteins, FrzA and FrzB. 
CheW-like protein are normally involved in the connection between the receptor 
and the kinase. We wondered why the Frz system needed two CheW. To better 
understand the function of FrzA and FrzB we first deleted each of the 
corresponding genes and looked at phenotypes.  
We found that the phenotypes are different from wt (Fig. 5.3); Figure 5.3 shows 
that FrzA is required for all the observed phenotypes and that is, thus, the core 
CheW of the system. On the other hand, FrzB is not required for the response to 
the isoamyl alcohol, a known activator of the Frz system [69-77], which suggests 
that this protein might have a different role.  
By aligning the protein sequences of FrzB and FrzA with that of the CheW from 
Thermatoga maritime (performed by research group of Dr. T. Mignot), we found 
that FrzB lacks a 20 amino acid region. To check whether this region have a 
function in the FrzB interaction on protein structure, the workshop where I did my 
time abroad, has been awarded the structural model of the FrzEP4-P5:FrzA and 
FrzEP4-P5:FrzB interactions by using the T. maritime CheAP4-P5:CheW crystal 
structure as template (Fig. 5.4), we found that the 20 amino acid region present in 
FrzA but not in FrzB, is predicted to form a two beta sheet (β4 and β5) loop located 
at the interface with the CheA P5 domain and specifically involved in the 
CheW:CheA interaction [78]. Our analysis, thus, suggests that FrzB lacks the FrzE 
binding region. 
To confirm that FrzB did not interact with its cognate histidine kinase, we performed 
bacterial two-hybrid assays. As expected, both FrzA and FrzB interacted with 
FrzCD as well as with the FrzCD signaling domain alone (FrzCDSD). On the other 
hand, only FrzA but not FrzB interacted with the FrzE P5 domain (FrzEP5). Neither 
FrzA nor FrzB could interact with the FrzCD N-terminal domain. These results 
altogether suggest that FrzB does not interact with FrzE.  
We then decided to construct a recombinant strain producing in the place of both 
FrzA and FrzB, a chimeric protein obtaining by introducing 21 amino acids from 
FrzA into FrzB at positions 476-497. The resulting strain responded to IAA (Fig. 
5.3), meaning that the chimera could bind the histidine kinase.  
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Figure 5.3: The Chimera phenotypes. 
For S-motility it was used a plate with CYE agar at 0.5%; for fruiting bodies was used a plate with CF 
agar at 1.5%; for the  IAA response was used a plate with CYE agar at 0.5% and 0.15% IAA. 
By phenotypes, therefore, it is clear that FrzA is the kinase of the main system and that the addition on 
a to beta sheets from FrzA (B4 and B5) to FrzB, allowed this protein to act as a real CheW. 
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Figure 5.4: Model structure of FrzA/FrzE and FrzB/FrzE. 
B lacks a part of A, composed of two beta sheets, which connects it to the kinase 
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5.4 Production of a FrzCD∆131-180mutant  
Canonical receptors from E.coli, consist of a transmembrane domain, a 
ligand binding domain, a HAMP domain, and a signaling region. HAMP is a flexible 
region that changes when the receptors senses the signal and transfers the 
conformational change to the domain of methylation (shaped of hook in figure 
5.5a).  
Instead, the FrzCD receptor from M. xanthus, does not have transmembrane 
domains and has a HAMP domain degenerated. It is therefore a cytoplasmic 
receptor (figure 5.5b). This receptor binds to the bacterial nucleoid, employing it as 
a support to recruit all signal proteins. The region extending from aa 7-27 was 
identified as a positively charge peptides that has a very important role in DNA-
binding [79] while the region ranging from 131 to 180 has unknown function. To 
understand the role that the 131-180 portion has within the genome, the deletion of 
this same portion was carried out, thus creating a new mutant called frzCD∆131-
180. After obtaining the plasmid to construct the mutant of interest, transformation 
of the M. xanthus cells with the plasmid of interest was performed. Once carried 
out a screening of the colonies, we continued with the selection with the galactose 
to lop out the plasmid and have a clean deletion mutant. 
This is because if it takes place on a single recombination, the wt gene will be 
reconstituted, allowing the formation of a halo around the colony. Otherwise if both 
recombinations occur there will be a rearrangement of genes and you will get our 
mutant of interest having colonies lacking of halos. 
Having used a double-recombinant system, this type of selection will guarantee us 
that colonies not presenting a halo have had a double-recombinant system and will 
be therefore mutants of interest. 
In our phenotype analysis (Fig. 5.6), we can see that, unlike wt, the frzCD∆131-180 
mutant , shows no colony expansion and no fruiting bodies. This phenotype is due 
to the fact that cells are hyper-reversing and cannot produce a net swarming. 
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Figure 5.5: a) canonic receptor of E.coli; b) receptor of M.xanthus. 
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  Figure 5.6: The FrzCD∆131-180mutant  phenotypes.  
For S-motility it was used a plate with CYE agar at 0.5%; for fruiting bodies was used a plate with CF 
agar at 1.5%; 
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5.5 Materials and methods 
Strains used in this thesis are: DZ2 WT, EM523 (∆frzA), EM524 (∆frzB), 
EM605 Chimera frzAB, EM525 (∆frzCD), frzCD ∆ 6-182, frzCD ∆ 6-130, frzCD ∆131-
180 #1,  frzCD ∆ 131-180 #6.  
Vectors used in this thesis are: pETPhos  and pBJ113.  
Plasmid used in this thesis is pEM467. 
For sequencing, it was used the company GATC Biotech.  
 M. xanthus strains were grown at 32°C in CYE rich media over night. Plasmids were 
introduced into M. xanthus cells by electroporation. These strains were obtained by 
homologous recombination based on a previously reported method using the pBJ113 
or pBJ114 vectors [77-80].  
Escherichia coli cells were grown under standard laboratory conditions in Luria-
Bertani broth supplemented with antibiotics if necessary. 
For swarming assays, cells (5 μl) at a concentration of 5×109 cfu ml−1 were spotted 
on CYE agar plates and incubated at 32°C and photographed after respectively 48h 
with an Olympus SZ61 binocular stereoscope. For predation assays, M. xanthus cells 
(3μl at a 1 concentration of 5×109 cfu ml−1) were spotted at 0.7 mm distance from 
each other on CF agar plates, incubated at 32°C and photographed after 72 h. 
 
Land used for the growth of phenotypes, are: 
- S-motility: CYE agar at 0.5%; 
- Fruit Bodies: CF agar at 1.5%; 
- IAA response: CYE agar at 0.5% and IAA at 0.15%. 
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